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SUMMARY 
Tuberculosis (TB) is an infectious disease which has plagued society for thousands of 
years. Despite public health programs, anti-TB drugs and a vaccine, the absolute numbers 
of people infected with TB each year continue to rise as populations grow. The high TB-
burden areas are also plagued by other debilitating factors including HIV/AIDS infection, 
poverty and malnutrition. Nutrition has been implicated in TB susceptibility in a number of 
studies. While most are observational reports made during times of war, famine or natural 
disaster, multiple studies provide convincing evidence for poor nutritional status increasing 
the morbidity and mortality of TB.  
Numerous approaches are currently utilized in TB research, and there has been 
convincing evidence to support the role of host genetics in TB susceptibility. Based on 
previous linkage studies and a search of current literature, three genes were selected for 
this case-control study. Subsequently, variations located in cathepsin Z (CTSZ), 
melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R) were genotyped in 
the South African Coloured (SAC) population to determine the existence of an association 
with TB disease.  
CTSZ is a lysosomal cysteine protease expressed in cells of the immune system. 
Interaction between this 303 amino acid protein and β2 integrin receptors lymphocyte 
function-associated antigen-1 (LFA-1) and macrophage antigen-1 (MAC-1) leads to altered 
lymphocyte proliferation. As a result, a single exonic variant in CTSZ, rs34069356, the 
same identified in a previous linkage study, showed strong evidence for association with 
TB susceptibility in cases (n = 410) and controls (n = 301) in the SAC population (p< 
0.0001). 
MC3R and MC4R are two of 5 melanocortin receptors. MC3R has been found to be a key 
regulator in energy expenditure and host metabolism while activation of MC4R leads to a 
decrease in food intake. Activation of these two receptors is regulated by leptin, a hormone 
released by adipose tissue. A variant located upstream of the MC3R gene, rs6127698, 
also showed evidence of disease association with the less frequent allele, T, being under-
represented in cases (n = 540) compared to controls (n = 541) (genotypic frequency, p = 
0.0039), suggesting a possible resistance phenotype. Functional analysis of this variant 
revealed an increase in MC3R expression when stimulated with BCG, with individuals 
homozygous for the T allele exhibiting an even larger upregulation of MC3R expression 
than individuals homozygous for the G allele, though this difference was not statistically 
significant. A single haplotype in MC3R was found to be associated with TB susceptibility 
(p = 0.0008) and this association remained after permutation testing to correct for multiple 
testing (p = 0.0061) 
Three variants were selected for genotyping in MC4R and while none of these showed a 
statistically significant difference between cases (n = 510) and controls (n = 487), this gene 
should not be ruled out as both MC3R and MC4R have been found to work closely though 
not redundantly and double knockout experiments result in exacerbated obesity, 
suggesting that these proteins have a synergistic effect. 
The results of this study support both a role of host genetics and nutritional status in TB 
and strongly motivate further research in both of these fields. 
  
 
OPSOMMING 
Tuberkulose (TB) is ‘n aansteeklike siekte wat reeds vir eeue die gesondheid van die 
publiek bedreig. Ten spyte van publieke gesondheidsprogramme en verskeie anti-TB 
medikasie middele, groei die aantal van mense wat hiermee ge-infekteer word steeds 
jaarliks. Dit is veral in areas waar TB steeds groei, waar ook ander neerdrukkende faktore 
soos HIV/Vigs, armoede en wanvoeding hoogty vier. Na aanleiding van verskeie verslae 
tydens oorloë, hongersnood en ander natuulike rampe is dit veral duidelik dat swak 
nutriënt inname morbiditeit en sterftes wat met TB gepaard gaan verhoog. 
Talle benaderings word tans gebruik in TB-navorsing, Bewyse is oortuigend om die rol van 
genetika van die gaheer met vatbaarheid vir TB te verbind. Op grond van vorige studies en 
die huidige literatuur, het ons drie gene gekies vir hierdie pasiënt-kontrole studie. Variante 
geleë in cathepsin Z (CTSZ), melanocortin 3 receptor (MC3R) en melanocortin 4 receptor 
(MC4R) is ge-genotipeer in die Suid-Afrikaanse Kleurling bevolking (SAK) (540 gevalle en 
540 kontrole) om sodoende die assosiasie met TB te bepaal. 
CTSZ is ‘n lisosomale sisteïen protease wat uitgedruk word in immuunselle. Interaksie 
tussen hierdie 303 aminosuur protein en β2 integrin reseptore nl. LFA-1 en MAK-1 bring 
veranderde limfosiet proliferasie mee. ‘n Enkele eksoniese variant in CTSZ, rs34069356, 
dieselfde soos ge-identifiseer in ‘n vorige studie, verskaf sterk bewys vir assosiasie met TB 
vatbaarheid in gevalle (n = 410) en kontrole (n = 301) in die SAK bevolking. 
MC3R en MC4R is twee van 5 melanokortien reseptore. Daar is gevind dat MC3R 'n 
sleutelrol speel in die energie regulering van gasheer metabolisme, terwyl die aktivering 
van MC4R eindelik lei tot 'n afname in voedsel inname. Aktivering van hierdie twee 
reseptore word gereguleer deur Leptien, 'n hormoon wat vrygestel word deur adipose 
weefsel, ‘n Variant, stroomop geleë vanaf MC3R, rs6127698, is ook bewys om met TB ge-
assosieer te wees, met die T-alleel meer seldsaam in gevalle (n = 540) as in kontroles (n = 
541) wat dui op 'n moontlike weerstandsfenotipe. Funksionele analise van hierdie variant 
onthul 'n toename in MC3R uitdrukking wanneer gestimuleer met BCG, met individue 
homosigoties vir die T-alleel wat selfs groter opregulation veroorsaak wanneer vergelyk 
word met individue homosigoties vir die G allele. Hierdie resultaat was egter nie statisties 
beduidend nie. 'n Enkele haplotiepe in MC3R is ge-assosieer met TB vatbaarheid en die 
assosiasie is onveranderd nadat ‘n permutasie korreksie aangebring is (p = .0061). 
Voorts is drie variante gekies vir genotipering in MC4R en ten spyte daarvan dat nie een 
daarvan 'n statisties beduidende verskil getoon het tussen pasiënte (n = 510) en kontroles 
(n = 487) nie, behoort hierdie geen nie uitgesluit word nie, Die rede hiervoor is dat beide 
MC3R en MC4R verskeie kere gevind is om in samewerking ‘n rol te speel om vetsug te 
voorkom of te vererger. 
Die resultate van hierdie studie beaam beide 'n rol van gasheer genetika en voedingstatus 
in TB en motiveer veral verdere navorsing in beide van hierdie vakgebiede. 
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CHAPTER 1: Introduction 
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A. Setting the Stage 
1.1 Tuberculosis  
Once thought to be near elimination, Mycobacterium tuberculosis (M. tuberculosis) has re-
emerged as a foremost concern in developing countries. In a report published by the 
World Health Organization (WHO) in 2009, it was estimated that tuberculosis (TB) was 
responsible for 1.3 million deaths in 2008 alone [1]. Despite the existence of a vaccine, 
numerous antimycobacterial drugs and treatment supervision programs, it is predicted that 
there will be 9.8 million new cases of TB in 2010, the highest in history [2]. Approximately 
one third of the world’s population is currently infected, with the majority of infections 
occurring in developing countries. Progression of TB is influenced by numerous factors 
including genetics, stress, malnutrition, poor sanitation and crowded living conditions [3]. 
While several genes have been implicated as having a role in TB infection, researchers 
have not yet determined how M. tuberculosis is able to evade the host immune system 
and persist for years as a latent infection.  
Only 10% of those infected with M. tuberculosis will go on to develop active disease but 
factors affecting how this occurs have yet to be established [4]. In order to gain control of 
this high burden disease and develop more effective prevention and treatment strategies, 
researchers must gain insight into the pathogenic mechanisms of M. tuberculosis.  
1.2 History 
TB is a disease that has plagued society for thousands of years. While effective public 
health programs have dramatically reduced TB morbidity in the Western world, TB remains 
one of the biggest killers in developing countries [5]. Epidemiological data suggests it was 
during the establishment of social networks consisting of about 200 to 440 people, 
approximately 10 000 years ago, that M. tuberculosis found its niche, quickly becoming 
endemic in human populations [6]. The migration of populations in Europe, the expansion 
of cities and the rise in population density during the 1600s provided optimal growing 
conditions for M. tuberculosis [6]. As living conditions worsened, TB spread and during the 
18th and 19th centuries TB became the leading cause of death in Western Europe [6]. It is 
estimated that one quarter of Europe’s population died of TB in the 19th century and TB 
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mortality did not decrease until sanitation and living conditions improved [7]. When 
Europeans emigrated to the New World in the 1800s, large urban areas like Boston and 
New York experienced TB mortality rates of almost 700 out of 100 000 [7].  
The discovery of antibiotics effective against TB and the use of the bacillus Calmette-
Guérin (BCG) vaccine resulted in a brief decline in TB morbidity and mortality in the 20th 
century. This decline caused health professionals to consider TB to be a disease of the 
past and research funding was decreased until 1972 at which point it was eliminated 
entirely from the budget of the Center for Disease Control in the United States of America 
(USA) [6]. It took 9 years for this funding to be reinstated. The rise in TB incidence in the 
USA during the mid-1980’s was due to increases in homelessness and poverty and the 
emergence of the Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency 
Syndrome (AIDS) [8]. The USA and England were able to decrease TB morbidity and 
mortality only after a dramatic increase in funding which was largely allocated to the direct 
monitoring of antibiotic treatment [8].  
The developing world continues to suffer from TB with TB incidence between 100-300 in 
100 000 people in Asia and Western Russia (compared to 10 in 100 000 in North 
America). Even these numbers are not as high as those of Southern and Central Africa 
where TB incidence is over 500 per 100 000 people [8] (Figure 1.1).  
1.3 Pathogen & Pathogenesis 
M. tuberculosis is an aerobic pathogenic bacterium with a circular chromosome of 
4 411 523 base pairs (bp) (65.6% G+C content) measuring 0.3-0.6 and 1-4 µm in width 
and length, respectively [9, 10]. This rod-shaped bacterium is weakly Gram-positive and 
classified as an acid-fast bacteria as it cannot be decolourized by acid alcohol [11]. M. 
tuberculosis has a complex cellular envelope composed of long-chain fatty acids, 
glycolipids and a number of other components which makes it exceedingly difficult to treat 
[10]. It is the slow growing nature of this bacterium that allows for chronic infection, 
requires long term treatment and complicates the diagnosis [12].  
When M. tuberculosis is inhaled as an aerosol into the lungs, it is phagocytosed by 
alveolar macrophages which envelope it in a phagosome [10, 13]. Once in the 
phagosome, engulfed agents are typically processed for antigen presentation or 
elimination from the host. In the case of M. tuberculosis, elimination does not always 
occur. When infected macrophages are unable to remove the tuberculous material, a 
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granuloma is formed as infected macrophages are surrounded in concentric layers by a 
variety of immune cells (Figure 1.2) [14]. The composition of a granuloma depends on the 
infectious agent it is controlling. Tuberculous granulomas are composed of macrophages, 
T and B lymphocytes, dendritic cells, neutrophils, fibroblasts and epithelioid cells [10, 15].  
 
 
Figure 1.1 Prevalence of TB in 2007 as estimated by WHO: TB prevalence is highest in Central 
and sub-Saharan Africa with over 500 per 100 000 being infected with TB (Figure taken from the 
WHO website). 
 
Through concurrent evolution with its host, M. tuberculosis has acquired the ability to both 
evade the host immune response and use certain components of the host immune system 
to its own advantage. From within the granuloma, the bacteria has access to host lipids 
which provide an abundant source of nutrients allowing it to persist for years [14]. Necrotic 
cavities can develop at the center of these granulomas which result in significant damage 
to the lung tissue upon granuloma rupture [4, 16]. The granuloma is beneficial to both the 
host and the bacilli as it protects the host from further spread of infection and shields the 
bacteria from elimination by the host [16]. Determining how M. tuberculosis is able to 
evade the host immune system and persist within these granulomas will play a major role 
in developing more effective treatments against TB infection. In times of stress (HIV/AIDS 
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infection, malnourishment, poverty, etc.) the strength of the host immune response can 
deteriorate. During this period of immunological stress, the bacteria can resume 
multiplication leading to the erosion of the granuloma wall and the release of M. 
tuberculosis into the airway [8, 16].  
 
Figure 1.2 Depiction of TB Progression: A. Aerosols containing minute numbers of the TB bacilli 
are inhaled and become engulfed by macrophages in the lung. B. Ninety percent of individuals are 
able to effectively contain the bacteria through the formation of granulomas which can last for 
years, never allowing the bacteria to spread. C. In ten percent of individuals, the bacteria is able to 
persist in the granuloma and multiply until the point of granuloma rupture, releasing numerous 
bacteria into the surrounding lung space. Adapted from [10]. 
1.4 Host Metabolism 
Prior to the discovery of effective antimycobacterial drugs, a diet rich in calories, protein, 
fats, minerals and vitamins was generally considered to be an important, if not essential 
factor, in treatment of TB [17]. There exists a multitude of evidence which supports an 
important role for nutrition in developing active TB and determining the severity of disease. 
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Most of the studies investigating the link between nutrition and TB are merely 
observational reports during times of war, famine or natural disaster [17]. The majority of 
these studies are flawed in a number of ways with respect to sampling methods, sample 
sizes, definition of malnutrition and assessment of infection [17]. Despite these 
complicating factors a number of studies exist which present convincing evidence for such 
an association. During the First World War, Denmark experienced a TB epidemic when 
locals suffered from a diet lacking in protein, vitamins and minerals as the country was 
exporting the majority of its meat, fish, poultry and dairy products [17]. It wasn’t until the 
German blockade of Denmark, when the Danes experienced a surplus of these foods, that 
there was a dramatic decrease in TB rates whilst infection rates of TB in surrounding 
countries continued to climb [17].  
The impact of proper nutrition was also seen in Norway. In the early 20th century, naval 
recruits in Norway experienced a higher than normal rate of TB infection believed to be 
caused by crowded and unhygienic living conditions [17]. Despite improvements in 
housing and hygiene, there was no major change in infection rates. Once recruits received 
a diet supplemented with margarine, cod liver oil, whole wheat bread, fresh fruit and milk, 
TB morbidity decreased significantly [17].  
Perhaps one of the most revealing studies was that of Leyton who made observations in a 
prisoner of war (POW) camp in Germany in 1946 [18]. In this camp, British and Russian 
POWs were housed under similar living conditions and subjected to similar types of 
manual labour. The British POWs received supplements from the Red Cross in the form of 
meat, cheese, fish, milk and vitaminized margarine. This added up to approximately a 
thousand extra calories a day compared to their Russian counterparts [18]. Leyton 
investigated a number of diseases prevalent in the prison (both acute and chronic) 
including malaria, dysentery, nephritis and diabetes but the only disease which showed 
significant difference was the incidence of TB [18]. Infection rates of British POWs were 
found to be 1.2% while those of Russian prisoners were as high as 15% [18].  
Numerous studies have shown that TB patients exhibit a reduced nutritional status when 
compared to healthy controls [19]. Measurements of body mass index (BMI), skin fold 
thickness and arm muscle circumference recorded in these studies provide convincing 
evidence which supports the occurrence of muscle wasting upon progression from TB 
infection to TB disease. One study performed in the USA reported that weight loss was a 
common symptom in 45% of TB patients with 26% showing signs of persistent anorexia 
[19]. TB-associated wasting is likely caused by a decrease in patient appetite resulting in a 
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decreased energy intake [20]. A study performed by Paton et al. [20] found that patients 
with TB-associated wasting weighed an average of 12 kg less than controls. TB 
susceptibility is also affected by an individual’s BMI prior to development of active disease. 
A study performed in 2010 in HIV-infected individuals from South Africa found an 
increased BMI to reduce the risk of both morbidity and mortality of TB even after correcting 
for CD4 counts [21]. 
The cause of TB-associated wasting continues to evade researchers. One possible 
candidate is leptin, a key mediator of energy metabolism implicated in the development of 
anorexia in patients with chronic inflammatory states [22, 23]. This protein is the product of 
the ob-gene and the binding of leptin to its receptors located in the hypothalamus results in 
the suppression of appetite [24]. Leptin is produced by adipocytes and studies have shown 
that levels of leptin are decreased during times of starvation as fat stores become depleted 
[24-26]. In 2002, two studies published conflicting results on the association of leptin to 
TB-induced wasting. A study conducted in Indonesia which found that plasma leptin levels 
were significantly suppressed in TB patients was contradicted by a study performed in 
London which found no such association [23, 27]. This discrepancy may to some extent be 
explained by leptin being regulated by antagonistic mechanisms. Decreased plasma leptin 
levels have been previously associated with fasting but have also been found to increase 
in response to mediators of inflammation [22, 24-26]. Further studies investigating the role 
of leptin in both inflammation and wasting could provide valuable insights into TB-
associated wasting.  
 
B. Exacerbating the Epidemic 
1.5 Bacterial Factors: Latency & Drug-Resistance 
Latent TB infection (LTBI) is clinically defined as previous infection with M. tuberculosis 
with no clinical symptoms of TB disease [28]. This form of TB infection still exhibits an 
immune response to TB antigens as utilized by the tuberculin skin test and is the most 
common form of TB infection (currently infecting one third of the world’s population) [28]. 
The ability of M. tuberculosis to persist within the host has proven to be one of its biggest 
strengths. Within the first weeks of infection, the bacilli multiplies rapidly but it slows its rate 
as increasing numbers of T-lymphocyte, monocytes and macrophages are recruited to the 
infection site [29]. As discussed in Section 1.3, during effective control of TB infection, a 
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granuloma is developed around infected macrophages which protect the host from the 
further spread of infection. These granulomas, however, also provide a safe haven for the 
bacteria, protecting them from complete elimination by the host. During times of 
immunological distress, the bacterium is able to resume multiplication and progress to 
active disease. How the bacterium is able to initially avoid elimination and persist within 
the host for years is still under investigation but the study of latent infection is complicated 
by the lack of an appropriate animal model. While a variety of animal models have been 
utilized for latency studies, none are an accurate representation of latent infection in 
humans [30]. LTBI is treated in some areas but the usefulness of LTBI treatment is 
controversial. A number of clinical trials have shown that LTBI treatment can reduce but 
never eliminate the risk of TB disease and poor adherence to the treatment (due to 
treatment length and side effects) is thought to lead to the emergence of drug-resistance 
[30]. In addition, current drugs used for LTBI treatment are the same as those used to treat 
active disease, including isoniazid and rifampin/pyrazinamide. Since most anti-TB drugs 
target cell wall components they are most effective on actively replicating bacteria [30]. It is 
imperative that drugs are developed which target the bacilli in the resting state in order to 
effectively eliminate the bacteria from the host. 
Drug-resistance has existed almost since the first use of antibiotics. Dubos reported that 
M. tuberculosis bacilli became resistant to streptomycin a few weeks to a few months 
following treatment [7]. Incomplete treatments increase the likelihood of an individual 
developing a drug-resistant strain of TB. Drug-resistant strains fall into one of two 
categories: multidrug-resistant (MDR) and extensively drug-resistant (XDR). MDR strains 
of M. tuberculosis are, by definition, resistant to rifampicin and isoniazid and may or may 
not have other drug-resistance [31]. The treatment for this category of M. tuberculosis lasts 
even longer than regular treatment and is a combination of more costly and less effective 
antibiotics which are even more poorly tolerated by patients [31]. The highest incidence of 
MDR-TB is in Eastern Europe where 10% of new cases and 40% of previously treated 
cases are MDR. In the remainder of the world, it is estimated that 5% of TB patients have 
MDR strains of which 40% are patients who have been previously treated for TB [32]. 
WHO estimated that each year there are 490 000 new cases of MDR-TB resulting in over 
130 000 deaths [31, 32]. XDR-TB is characterized by resistance to rifampicin and isoniazid 
as well as any quinolone and at least one injectable second-line agent (capreomycin, 
amikacin, kanamycin) [31, 32]. The present increasing prevalence of drug-resistant TB 
makes TB a concern once again on an international scale. This is illustrated by a study of 
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TB prevalence in Berlin, Germany [33]. Germany is currently classified as a low-incidence 
country with respect to TB prevalence with a TB incidence rate of 6.1 per 100 000 and a 
mortality rate of 0.2 per 100 000 in 2007 [33]. It was found that 43% of TB patients 
identified in Germany were born outside the country and 80% (53 of 66 patients) of those 
found to be infected with MDR-TB were also foreign born [33]. Another study which 
investigated XDR-TB in California, USA also found that 83% of XDR-TB patients were 
foreign born and half of those had immigrated to the USA less than 6 months prior to 
diagnosis [34]. Even in a developed country like the USA, patients diagnosed with XDR-TB 
who were HIV-negative had a mortality rate 41% (results based on known final outcomes 
of 12 of the 18 patients diagnosed with XDR-TB between 1993 and 2006). In developing 
countries concurrently battling HIV/AIDS, poverty and malnutrition, mortality rates are 
expected to be much higher. These studies clearly indicate that attention must be paid on 
an international scale to the prevalence of all forms of TB and an increase in global 
morbidity will exacerbate the spread of drug-resistance. 
1.6 Host Environmental Factors 
While it is clear that TB is most prevalent in areas suffering from poverty, the reasons for 
this might not be as apparent. A study conducted at The Bushullo Major Health Centre 
located in the Southern Nations, Nationalities and People’s Region of Ethiopia in 2005 
illustrates some of the issues with treating TB in such regions. Cambanis et al. [35] 
reported that based on interviews conducted with 243 TB-suspected patients, 51% had to 
borrow money and an additional 22% had to sell personal property (including cattle and 
grain) to afford the trip to the health center. This study also found that 85% of surveyed 
patients waited more than 10 days from the onset of symptoms before seeking medical 
attention and major reasons for this included cost of transport, prolonged transport times 
(including overnight trips) and the need to sell personal belongings [35]. A report published 
in 1991 also found that poverty affected treatment compliance [36]. Farmer et al. [36] 
reported that in extremely poor countries there is massive drop-out from treatment 
programs. However, even where TB programs are established, there exists a lack of 
follow-up and a need for accurate record keeping [36]. A more recent study investigating 
possible solutions to the ongoing battle of treatment compliance was that by Belo et al. 
[37] which reported that the poorest patients had longer transit times which resulted in 
longer wait times between symptom onset and visiting a health facility. A possible solution 
to this issue is the introduction of incentives to encourage patients to seek medical 
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attention sooner and complete the course of treatment. The authors found that the top five 
incentives as ranked in a survey conducted in the Rio de Janeiro state of Brazil were 
access to laboratory tests, home drug delivery, food allocation, ticket transportation and 
scheduled appointments [37]. With a curable disease like TB, one of the main obstacles to 
elimination of this disease is treatment compliance. The introduction of incentives may be 
a plausible method of increasing treatment compliance and subsequently decreasing TB 
incidence. 
Based on the current global distribution of TB, it is apparent that those areas most afflicted 
remain those concurrently suffering from over-crowding, poverty and malnutrition. Not 
surprisingly, nearly half the population of sub-Saharan Africa is currently living below the 
international poverty line, and chronic hunger afflicts 1 in 5 people in the developing world 
[38-40]. Chronic hunger increases susceptibility to disease, decreases learning ability and 
reduces the individual’s ability to work resulting in a further increase in poverty. Much as 
there appears to be a bi-directional effect between poverty and chronic hunger, there also 
appears to be a bi-directional interaction between TB and malnutrition (Figure 1.3). For this 
reason, studying the effects of nutritional status on the development of TB and the impact 
of active TB on nutritional status has proven to be a difficult task. This problem is 
aggravated by a number of other environmental factors including, but not limited to, poor 
public healthcare systems and unhygienic living conditions.  
In areas plagued by poverty, malnutrition and TB, each entity seems to intensify the 
prevalence of the other two. It would seem that addressing any one of these issues would 
have a positive impact on all three. Further examples of the impact of nutritional status on 
TB are discussed in Section 1.4 which deals with host metabolism.  
Unlike TB, a disease which has plagued society for centuries, HIV/AIDS was only 
recognized in 1981 and the collision of these two epidemics has had disastrous 
consequences. HIV/AIDS is an infectious disease transferred by the exchange of bodily 
fluids and by exposure to contaminated blood or blood products [41]. Infection with HIV 
results in a dramatic decrease in circulating levels of CD4 T-lymphocytes, effectively 
weakening the host immune system. Once CD4 counts drop below 200 cells/mm3 (from 
1500 cells/mm3 in healthy individuals), patients exhibit increased susceptibility to a variety 
of opportunistic infections [42]. Similar to TB, the burden of HIV/AIDS is felt most in 
developing regions of the world including South and South-East Asia and sub-Saharan 
Africa (Figure 1.4). A report by UNAIDS (a joint United Nations programme on HIV/AIDS) 
in 2009 estimates that as of December 2008 there were 33.4 million people currently living 
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with HIV/AIDS, 22.4 million of which were residing in sub-Saharan Africa [41]. In various 
areas of the world, many people, largely women, avoid HIV/AIDS testing and subsequently 
receiving treatment, for fear of shaming or being disowned by their families [43]. 
The stigma associated with HIV/AIDS has resulted in many individuals never receiving 
treatment which has allowed certain opportunistic infections to flourish. TB is currently the 
leading cause of death in individuals infected with HIV/AIDS [44]. Not surprisingly, sub-
Saharan Africa currently has the highest TB-HIV/AIDS co-infection rates worldwide with 
South Africa ranking number one (Figure 1.5). South Africa’s history has had a major 
influence on its current TB-HIV/AIDS co-infection status. Two major factors contributing to 
this co-infection status are apartheid, which segregated different populations, and the 
development of the mining industry with each creating environments ideal for the spread of 
infectious diseases. Poor sanitation, malnutrition and crowded living conditions allowed TB 
to thrive. Overcrowding and poorly-ventilated hostels where mine-workers resided which 
were regularly serviced by commercial sex-workers created the ideal situation for the 
spread of both HIV/AIDS and TB [44]. 
 
Figure 1.3 Bi-directional interaction of malnutrition and TB: Malnutrition leads to increased 
susceptibility to infectious diseases as a result of a compromised immune system. Increases in 
susceptibility increase disease prevalence. In the case of TB, infection leads to wasting in the form 
of lean tissue and adipocyte loss resulting in increased levels of malnutrition. Figure from 
Malnutrition and Tuberculosis by Macallan [40]. 
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Figure 1.4 Global HIV/AIDS revalence: A WHO report published in 2007 estimated that 39.5 
million people were infected with HIV/AIDS worldwide in 2006 (Figure taken from www.unaids.org) 
 
 
 
 
 
Figure 1.5 Estimated HIV/AIDS prevalence in new TB cases: In a report published in 2006, 
WHO estimated that HIV prevalence in TB incidence cases was highest in sub-Saharan Africa in 
2005 (Figure taken from the WHO website). 
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1.7 The Synergistic Effect 
The result of having all the issues discussed above being co-localized has been 
disastrous, the results of which may soon be felt on a global scale if not dealt with promptly 
and appropriately. Each issue appears to fuel the others resulting in some of the world’s 
most resource-rich countries being incapacitated by rampant disease, poverty and 
malnutrition. Effects of these issues are also felt in the industrialized world. Studies found 
that in the late 1980s and the early 1990s, HIV infection was associated with outbreaks of 
MDR-TB, frequently with patients succumbing to disease even before MDR-TB could be 
bacteriologically confirmed [45]. During an XDR-TB outbreak in KwaZulu Natal, South 
Africa 52 of 53 patients died an average of 16 days after diagnosis [46]. These 
exceptionally high mortality rates were a result of co-infection with HIV/AIDS; (of the 44 
XDR-TB patients tested, all tested positive for the virus) [46]. Genotyping of the TB strains 
showed that all XDR-TB patients were infected by genetically similar strains [46]. Having 
so many malnourished individuals living with HIV/AIDS and residing in poor, over-crowded 
living conditions dramatically increases the risk of exposure/re-exposure to TB and spread 
of increasingly virulent and untreatable strains of TB.  
C. Approaching the Solution 
1.8 Diagnostics 
Currently, only one standard method exists to detect latent TB infection. The tuberculin 
skin test (TST) which is also referred to as the Mantoux or purified protein derivative (PPD) 
test [47] is widely used but it is limited in a number of ways. The PPD used in this test is 
composed of antigens found in M. tuberculosis but also Mycobacterium bovis and other 
mycobacteria which can result in false positives in areas where the BCG vaccination is 
used [48]. The reverse problem, false negatives, is also an issue in areas plagued with 
HIV/AIDS as a compromised immune system can lead to anergy [49]. Aside from 
erroneous results, this method also results in poor follow up due the requirement of a 
return visit 72 hours after administration of the test as well as variability in dose of PPD, 
method of application and criteria of interpretation [49]. 
At present there exists a variety of methods which are used to detect active TB disease in 
patients but a definitive diagnosis requires culturing of M. tuberculosis bacteria from a 
patient specimen [50]. Due to the slow growing nature of M. tuberculosis, limitations of the 
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current detection methods and lack of proper disease seeking programs, it is estimated 
that each year more than 30% of new TB cases go undetected [1]. The most commonly 
used method of TB diagnosis in low-income countries is the sputum smear which was 
introduced over 125 years ago by Robert Koch [12]. This method detects the presence of 
acid fast bacilli but has a limited use as it cannot distinguish species or provide any 
information on drug-resistance. Chest radiography is also used to detect active TB but 
normal results or mild radiographic evidence each play a role in missed diagnoses [50]. 
Another major diagnostics tool is solid culture, but this method requires approximately 2 
weeks for a diagnosis [51]. Recent advances in culture techniques include the 
development of liquid culture diagnostics which have only a 2-day turn around period, but 
while they have a high specificity (83 - 100%) they lack sensitivity (21 - 83%) [52]. A 
variety of other techniques are currently in development but the practicality of their 
application may be limited in resource-poor settings. Nucleic acid amplification tests 
(NAAT) can provide results within one day. A number of reviews on this method suggest 
that it has a high specificity but exhibits poor and inconsistent results with respect to 
sensitivity and this method of TB diagnosis is even less sensitive when patients are TST 
negative (ie: HIV/AIDS endemic areas) [53]. The development of an immune-based 
diagnostic test have been attempted for decades but due to a wide ranging variability in 
the immune response, none have been able to completely replace microscopy and culture 
[53]. Difficulty in developing a serologically-based diagnostic test arises due to the different 
states in which M. tuberculosis may be found. It is thought that M. tuberculosis expresses 
different genes and proteins during active and latent infection [54]. 
Due to the currently limited ability to rapidly and conclusively diagnose active TB disease, 
missed diagnoses result in the perpetuation of TB transmission and increased morbidity. 
Even if a proper diagnostic test were to be developed, its influence on the morbidity and 
mortality rates of TB are likely to be minimal until proper disease seeking and drug 
adherence programs are in place. 
1.9 Drugs, Vaccines & Public Health Programs 
Where treatment is unavailable, TB mortality can be up to 60% and most of these cases 
occur in developing countries [9]. During the centuries in which TB has plagued society, 
physicians have struggled to find ways to treat diseased individuals. The more ancient 
procedures did nothing to cure the disease but merely alleviated the symptoms, making 
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patients feel as though they were getting better [7]. Today, there exist multiple antibiotics 
with which to treat TB which include streptomycin, isoniazid, rifampicin and pyrazinamide 
[8]. Despite all these treatments, TB has yet to be eliminated. Currently, the most effective 
treatment is the combination of 3 antituberculosis drugs administered over a 6 month 
period [55]. With a treatment period of this length, it is difficult to keep patients motivated to 
complete the course of antibiotics, especially when patient health improves in just 1-2 
weeks [55]. In addition to treatment length, many of the antibiotics currently used to treat 
TB are poorly tolerated by patients. Isoniazid can result in adverse neurological and 
hepatic reactions while rifampicin can result in allergic reactions including fever, rash and 
flu-like symptoms [56]. Adverse reactions to other first-line TB drugs include loss of visual 
acuity and colour vision (ethambutol), permanent deafness and nephrotoxicity 
(streptomycin) and hepatotoxicity and gastrointestinal intolerance (pyrazinamide) [56].  
The sole existing vaccine, the BCG vaccine, currently shows inconsistent efficiency (0-
80% in randomized control trials) [57]. It is thought that the original strain generated by 
Calmette-Guérin, shown to be an efficient vaccine for TB, has become increasingly 
attenuated over the years as subsequent passages of the vaccine have been produced 
[57]. While attempts to develop a new vaccine have been in progress over the past several 
years, none have been able to replace BCG. The lack of an appropriate animal model 
complicates the search for an alternative vaccine. Researchers are limited to using mouse 
and guinea pig models to test the activity of potential vaccines despite the mouse’s 
inability to replicate lung pathology and the guinea pig’s high susceptibility to infection [58].  
In an increased attempt to eradicate TB, WHO implemented a new program entitled 
Directly Observed Treatment and Short-course drug therapy (DOTS) [32]. Under DOTS, 
antibiotic treatment must be observed by health professionals to ensure that all antibiotics 
are taken and the entire treatment course is completed [55]. The use of patient registries 
which follow a patient from diagnosis to cure have a well-established precedent to improve 
public health [59]. With a patient registry, a patient’s progress can be tracked from 
diagnosis to cure but in developing countries, where governments and public healthcare 
systems are frequently unstable, this direct patient observation is extremely difficult [8]. In 
addition, the concept of treatment observation is insufficient since most TB patients only 
arrive at the clinic once extremely ill, likely exposing family and community members prior 
to seeking treatment. Surveillance programs which actively seek out individuals with active 
disease must be implemented if control over TB is ever likely to be accomplished. 
Ineffective public health measures, low interest in co-operation by patients, development of 
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drug-resistant strains and the emergence of HIV/AIDS has led to higher levels of TB 
infection than ever before [60]. 
1.10 Basic Sciences: Mycobacteriology & Immunology 
Through mycobacterial research, much information on the life cycle and metabolism of M. 
tuberculosis has already been gathered. Due to the current need for original preventative, 
diagnostic and treatment strategies, further research into the inner workings of M. 
tuberculosis is absolutely necessary. The release of the complete genomic sequence of M. 
tuberculosis has allowed researchers to identify new genes which may provide novel 
targets for drug therapy and insight into the complex interaction between host and bacteria 
[61]. Using the genomic sequence, researchers are able to utilize microarrays to measure 
gene expression which can aid in identifying critical genes and investigate the function of 
unknown genes [62]. Mycobacterial proteomics goes beyond the static mycobacterial 
genomic sequence and focuses on the actively expressed portions of the genome which 
may aid in identifying new areas for vaccine development [63]. Identifying differences in 
the protein profiles between active and latent disease may allow researchers to develop 
methods to diagnose the two separate disease states [62]. Determining translational 
control and post-translational modifications (PTMs) present in M. tuberculosis may provide 
researchers with a level at which to manage the progression to active disease and may 
provide novel targets for drug development. Mycobacteriological research alone is 
insufficient as the numerous strains have been shown to vary in fitness, virulence and 
persistence. Studies in conjunction with the host immune response to the various strains 
may provide valuable insight into the complex interaction between host and bacterium. 
An increased progression to active disease in immunocompromised individuals 
emphasizes the importance of the host immune response in effective control of the M. 
tuberculosis pathogen. While much research into the role of immunology has been 
performed, current knowledge of the mechanisms which play a role in protection against 
TB remains limited [64]. However, immunological research may play an important role in a 
number of areas crucial to effective TB control. As discussed in Section 1.8, much 
research has gone into the development of serological diagnostic tests for TB. While none 
as of yet have been able to replace microscopy or solid culture, further investigations may 
provide useful information in distinguishing disease state based on the detection of specific 
biological markers. By combining mycobacteriology and immunology, proteins which elicit 
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an appropriate immune response may be used to identify novel targets against which a 
vaccine can be developed. Immunological research is limited as it allows only for 
investigations to be performed on genes implicated in the host immune response. Because 
no single gene has been shown to be responsible for TB susceptibility it is important to 
identify new genes which currently have an unknown role in the immune response to TB 
infection. 
 D. Genetics 
1.11 Evidence for Genetic Component to TB Susceptibility  
A study conducted in 1990 of nursing home residents of Arkansas, USA showed that 
African-Americans were twice as likely to develop TB than Caucasians [65]. This suggests 
that some populations are more susceptible to TB than others. A possible explanation for 
the non-uniform distribution of TB comes from Haldane who suggests that over the past 
5000 years natural selection in humans has been influenced by microorganisms [66]. In 
regions plagued with malaria we can see selection in certain individuals for resistance to 
this protist by means of specific genetic mutations [66]. Similar trends can be seen with TB 
disease in the Qu’Appelle Indians who were first exposed to the M. tuberculosis in 1890 
[60]. Following the introduction of the bacteria, half the families died from TB infection. 
After 40 years the annual TB mortality rate dropped from initial levels of 10% down to only 
0.2% [67]. In the 18th and 19th century, TB killed one quarter of the European population, 
possibly selecting for a population with a higher resistance to TB [67]. Because TB has 
been prevalent for less than a hundred years in Africa, it is likely that African populations 
exhibit higher susceptibility to infection [68]. 
However, within a population or within a family, there are still individuals who appear to be 
more susceptible to TB than others. Studies have found monozygotic twins have a higher 
concordance for TB infection than dizygotic twins [68]. It appears that some individuals are 
better able to control TB infection than others. Support for this theory comes from an event 
which occurred in Lubeck, Germany in 1923. During what was supposed to be the routine 
vaccination with BCG, 249 babies accidently received virulent M. tuberculosis. Despite all 
infants receiving the same strain and same dose, only 173 survived [69]. It is therefore 
probable that the genetic make-up of each individual plays a role in how M. tuberculosis is 
handled by the host. 
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To better understand the mechanisms utilized by M. tuberculosis, it is necessary to further 
investigate the host immune response upon TB infection and identify new genes involved 
in TB pathogenesis and susceptibility 
1.12 Finding the Genes 
For many infectious diseases, there can be a complex interaction between microorganism, 
host and environment which influences the severity and progression of disease [70]. 
Genetics are known to play a significant role in the development of infectious diseases 
with some genetic variations being more influential than others [70]. TB is a complex 
disease with multiple genetic loci and multiple environmental factors contributing to its 
development [70]. Finding the genes involved in TB infection has proven to be a challenge 
[71].  
Certain factors can confound the search for disease-causing genes. One such factor is 
population stratification. Population stratification refers to the existence of a subpopulation 
whose genetic makeup differs significantly from the larger population due to differences in 
ancestry [71]. The result of this is the detection of spurious associations when performing 
case-control studies [72]. Linkage disequilibrium (LD) can also lead to erroneous results. 
LD is a measure of the proximity of two alleles at different loci on the same chromosome. 
The closer two alleles are, the less chance recombination will occur between them, giving 
them a higher LD value [72]. As a result of LD, the allele at one locus can frequently 
predict the allele at a second locus [73]. This can cause false positive results when an 
allele in LD with the disease-causing allele is investigated and an association is found. LD 
can be also useful as it can lead to the identification of the true disease-causing variant.  
A variety of methods are currently utilized by researchers to seek out loci, and 
subsequently genes, which show an association to disease. 
Linkage studies locate genes linked to particular phenotypes without any prior knowledge 
of biological function and are most useful at identifying rare variants [74]. Linkage analysis 
involves using naturally occurring polymorphisms as generic markers to create a genetic 
map from which the transmission of chromosomal regions in families can be traced [74]. 
No assumptions of inheritance mode are made allowing for an unbiased identification of 
regions of the genome that may contain potential susceptibility genes. This technique has 
increased the number of disorders linked to specific genes from roughly 100 in the late 
1980s to over 2200 today [75]. The affected sibling-pair method is a type of linkage study 
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which is frequently used to identify loci which show an association to a complex genetic 
trait [76]. This method attempts to identify regions of the chromosome which are inherited 
more frequently by affected siblings than would be expected to occur through chance 
alone [77, 78]. This method has been successful in diseases such as type 1 diabetes, 
asthma and inflammatory bowel disease [70]. Linkage analysis has proven useful as it has 
replicated previous associations and identified novel genetic variants which may have 
been missed by the hypothesis-driven approach [69]. By identifying polymorphisms 
located in non-genomic regions, linkage studies can lead to new hypotheses of the 
function of these regions and their involvement in disease [79]. Following the detection of a 
region showing evidence of linkage, further fine mapping of that region can allow for the 
identification of candidate genes with little or no previous association with that disease 
[70].  
Hypothesis-driven studies identify candidate genes based on results from animal models 
or mechanisms previously elucidated in humans and known to be involved in the 
development of disease [80]. This method allows for targeted investigations to be 
performed on SNPs suspected of being associated to a disease based on priori 
hypotheses [80]. Hypothesis-driven candidate gene association studies are cost effective 
as they focus research on genomic regions showing likely association to a specific disease 
as oppose to scanning the entire genome [70]. This approach can identify candidate 
regions through a number of ways. Animal models have been used to determine 
biochemical pathways and identify genes crucial to the pathogenesis of a particular 
disease [80]. Identifying these critical pathways in animal models allows for a targeted 
search of similar pathways in humans. Once identified, researchers can investigate all or 
specific genes involved in that pathway. Computer-based algorithms have also been 
utilized to identify candidate genes based on methods such as sequence comparisons 
against genes previously associated to disease development [79].  
Population-based case-control studies compare the frequency of selected genetic variants 
between affected and unaffected individuals [73]. This method is most frequently used to 
identify common polymorphisms underlying complex genetic traits [73]. Population-based 
case-control studies are most useful when thousands of affected samples can be collected 
however complications can arise when investigating a disease where the affection status 
is subjective [74]. One important aspect of this type of method is the selection of 
appropriate control samples. Controls must be selected from the same population group 
so that both case and control subjects have similar exposure rates and are influenced by 
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similar environmental and social factors. Despite careful selection of a control group and a 
clear definition of affection status, population-based case-control studies are prone to false 
positives caused by population stratification or LD since this type of study does not include 
population analysis [79].  
1.13 Genes Currently Implicated in TB Susceptibility 
A number of genes have already been implicated in TB susceptibility and have been 
studied to varying degrees in a number of populations. An in depth summary of these 
studies can be found in Table 1.1 (from a recent review by Möller et al. [81] which has 
been updated to include the most recent studies on genes associated to TB susceptibility).  
The genes listed in Table 1.1 have been identified through the use of the previously 
mentioned methods including both hypothesis-driven and linkage studies. Due to the 
number of factors which can lead to spurious results, attempts to find the true disease-
causing variants are frequently accomplished through the use of multiple methods, each 
with unique advantages and disadvantages. Using a multistage strategy, Cooke et al. [82] 
mapped a novel locus which showed an association to TB susceptibility in African 
populations. Beginning with an affected sibling pair linkage analysis, one genomic region, 
chromosome 20q13.31-33, showed evidence of association to TB susceptibility in a 
Coloured population from South Africa and Malawians from the Karonga district [82]. Using 
a population from Gambia, detailed association mapping within this region identified two 
genes showing evidence of disease association: cathepsin Z (CTSZ) and melanocortin 3 
receptor (MC3R) [82]. Polymorphisms in either gene which showed disease association 
were genotyped in two more West African populations, Guinea-Bissau and the Republic of 
Conakry [82]. A polymorphism in the 3’-untranslated region (UTR) in CTSZ rs34069356 
showed strong disease association with genotype distributions being similar across all 
three populations (p=0.005) [82]. Following regression analysis, the association seen in 
the MC3R polymorphism rs3827103 did not remain significant though a trend for a 
protective effect of the MC3R AA genotype did remain between cases and controls [82].  
Confirmation of these findings or further investigations as to the role of either of these 
genes in TB pathogenesis has yet to be performed.  
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1.14 Summary 
Most of the developing world already suffers from the effects of the most recent TB 
epidemic and as drug-resistance and HIV/AIDS become more prevalent it is likely that TB 
incidence will increase in all areas of the world. Further research is required to identify 
genes responsible for TB susceptibility so that mechanisms underlying TB pathogenesis 
can be elucidated. Only once the pathogenesis of TB is better understood can we hope to 
develop more effective prevention and treatment strategies and gain control of this 
disease. Evidence for a genetic component to TB susceptibility has been supported by 
numerous studies, however, no individual gene has been found to be associated to TB 
susceptibility in all populations. Inconsistent results may be explained by unequal 
susceptibility shown across different populations. Using a multistage strategy, a recent 
study identified a locus on chromosome 20 which showed association to TB susceptibility 
across a number of populations [82]. Further investigations will allow us to gain more 
insight into the role host genetics plays in TB susceptibility in order to identify new genes 
which impact events such as effective TB control, progression from latent to active disease 
and host resistance.  
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Table 1.1 Candidate genes previously associated to TB  
Gene Associated Population Ref. Not Associated Population Ref. 
HLA India [83, 84] India (South) [85] 
 
Mexico [86] China (Hong Kong) [87] 
 
Iran [88]   
 
Thailand [89, 90] 
  
 
Poland [91] 
  
 
South Africa (Venda) [92] 
  
 
Cambodia [93, 94] 
  
 
Indonesia [95] 
  
 
India [84] 
  
 
Russia [96] 
  
 
India (South) [97, 98] 
  
 
India (North) [99] 
  
 
Russia (Tuvinian) [100] 
  
 
Italy [101] 
  
 
Korea [102] 
  
 
China [103] 
  
 
Brazil [104] 
  
CCL2 
 
Ghana [105] China (Hong Kong) [87] 
Mexico [106] South African Coloured (SAC) [107] 
Korea [106] Russia [105] 
CD209 
 
SAC [108] Colombia [109] 
Gambia [110] Tunisia [111] 
Sub-Saharan Africa [110] Guinea-Bissau [110] 
  
India (South) [112] 
  
Republic of Guinea [110] 
  
Guinea-Bissau [110] 
  
 
Malawi [110] 
IFNG 
Sicily [113] West Africa [114] 
Croatia [115] India (South) [116] 
Caucasian [117] African American [118] 
China [119] Caucasian [118] 
SAC [120] USA (Houston) [118] 
Turkey [121] Japan [122] 
China (Hong Kong) [123] Indonesia [124] 
Colombia [125]   
MBL 
Spain [126] Tanzania [127] 
SAC [128] Poland [129] 
African America [130] USA (Houston) [130] 
Turkey [131] Caucasian [130] 
Italy [132] China [133] 
India [134] Gambia [135] 
Denmark [136] 
  
NOS2A 
Colombia (Paisa) [137] Mexico [106] 
African American [138] 
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Brazil [139] 
  
SAC [107]   
 
SLC11A1 
USA (Houston) [140] Japan [122] 
China [141-143] Thailand [90] 
Korea [144] Morocco [145] 
Tanzania [146] Gambia [147] 
Cambodia [93] Russia (Slavic) [148] 
Gambia [147] Taiwan [149] 
China (Han Chinese) [150, 151] Poland [129] 
Japan [152] 
  
Peru [153] 
  
SAC [154] 
  
Poland [155] 
  
Gambia [147, 156] 
  
USA (Caucasian) [157] 
  
Japan [158] 
  
Guinea-Conakry [159] 
  
Denmark [146] 
  
SP110 
Republic of Guinea [160] Guinea-Bissau [160] 
Gambia [160] SAC [161] 
  
Russia [162] 
  
 
Ghana [163] 
TLR1 
USA (African American) [164]   
 
USA [164]   
 
TLR2 
Korea [165] Guinea-Bissau [166] 
Turkey [167]   
TLR4 
  Gambia [168] 
  Guinea-Bissau [166] 
TLR8 
Indonesia [169] 
  
Russia [169] 
  
VDR 
Guinea-Bissau [166] Tanzania [127] 
India [170] South Africa (Venda) [92] 
Asia (Gujarati) [171] Cambodia [93] 
China (Han Chinese) [172] Peru [173] 
West Africa [174] Japan [122] 
Gambia [175] 
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2.1 CTSZ 
CTSZ, also known as cathepsin P (CTSP) or cathepsin X (CTSX), encodes the 303 amino 
acid protein cathepsin Z (CTSZ) [176, 177]. It is one of 11 lysosomal cysteine proteases 
(called cathepsins) that belong to the papain family and CTSZ is located on chromosome 
20 at position q13 [177]. Like all cathepsins, CTSZ is translated as an inactive peptide, 
requiring the cleavage of the proregion for activation [177, 178]. While the cathepsins vary 
in their physiological function and expression, CTSZ is expressed only in cells of the 
immune system [177, 179, 180]. 
Recent studies have found that active CTSZ co-localized with β2 integrins in monocytes, 
dendritic cells and lymphocytes and was found to regulate the activity of β2 integrins 
lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18) and macrophage 
antigen-1 (MAC-1; CD11b/CD18) [177]. Interactions between CTSZ and the β2 integrins 
LFA-1 and MAC-1 regulate leukocytes proliferation, cellular adhesion and migration, 
phagocytosis and activation of T- lymphocyte [181]. Integrins are one of six families of cell 
adhesion molecules and all integrins are heterodimers composed of one α and one β 
subunit [181]. The integrin family is subdivided into three main classes: β1, β2 and β3 and all 
function in cell-cell and cell-matrix adhesion [181]. While β1 and β3 integrins are co-
expressed on most cell types, β2 integrin expression is limited to leukocytes [182]. Integrins 
play an important role in the extravasation of leukocytes across the epithelium into tissue 
(i.e. an infected lung) [183]. LFA-1 and MAC-1 are known to have a central role in 
leukocyte migration into sites of infections and inflammation as well as into lymphoid 
organs (for immunosurveillance) [184, 185]. Using vesicular staining, Obermajer et al. 
[179] found that in pro-monocytic U-937 cells, CTSZ localized in the perinuclear region but 
once differentiated, protein localization was most pronounced at the perimembrane region. 
Within a number of cell types, CTSZ was found to co-localize with β2 integrins near the 
membrane and in differentiated macrophages and dendritic cells, interaction between 
CTSZ and β2 integrin MAC-1 resulted in increased cellular adhesion [179, 180]. Within T-
lymphocytes it has been shown that CTSZ co-localizes with LFA-1 at cell-cell junctions 
and is responsible for the activation of this β2 integrin [180]. Based on in vitro experiments, 
it has been postulated that CTSZ activates LFA-1 through the sequential cleavage of C-
terminal amino acids F766, A767, E768 and S769 until it reaches P765 which is resistant to 
CTSZ proteolytic cleavage (Figure 2.1) [177]. LFA-1 activation within T-lymphocytes leads 
to increased lymphocyte proliferation while MAC-1 activation from within macrophages and 
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dendritic cells results in the suppression of lymphocyte proliferation [180]. Both lymphocyte 
proliferation and cellular adhesion are important in effective control of microbial infection 
and the formation of granulomas. Yassin et al. [186] found that TB patients showed 
increased expression of CD11/CD18 on monocytes. It is plausible that interference with 
leukocyte migration and proliferation or in cellular adhesion may lessen the host’s ability to 
effectively control mycobacterial infection. 
2.2 MC3R  
MC3R is one of five melanocortin receptors (MCRs) which belong to the family of G 
protein coupled receptors (GPCRs), each with seven membrane spanning regions and all 
transmit their signals through the activation of adenylate cyclase [187]. The main agonist 
for each MCR is α-melanocyte stimulating hormone (α-MSH). As previously mentioned, 
MC3R is located on chromosome 20q13, as is CTSZ and encodes a 361 amino acid 
protein [188]. The melanocortin 3 receptor protein (MC3R) is abundantly expressed in 
several brain regions and in a variety of peripheral tissues including the placenta, heart, 
gut and immune cells [184, 189, 190]. Unlike the other 4 MCRs, MC3R is the only MCR 
which is activated by γ- MSH to the same extent as α- and β-MSH [188]. MC3R has been 
shown to play a role in a variety of biological systems including the regulation of energy 
homeostasis and fat metabolism, regulation of the cardiovascular system and inflammation 
[191-197]. Defects in MC3R can result in decreased total expression, intracellular retention 
and defective receptor activation [192, 198-204]. Several studies have been performed 
investigating the association of obesity to various polymorphisms in MC3R [191, 192, 194, 
197, 205]. Using a mouse model, Chen et al. [199] showed that inactivating mutations of 
MC3R led to an increase in fat mass with a corresponding decrease in body mass without 
any change in eating behavior or metabolic rate. One of the key regulators of MSH levels 
is leptin. Leptin is released from adipocytes and acts to modulate appetite and energy 
expenditure. Leptin levels are proportional to the number of adipocytes and remain 
relatively constant despite daily variations in energy consumption and expenditure [206]. 
Leptin increases MSH levels by increasing expression on pro-opiomelanocortin (POMC), 
the precursor to MSH. When leptin crosses the blood/brain barrier, it binds to the leptin 
receptor expressed on melanocortin neurons and increases the expression of MSH. 
Binding of MSH to MC3R results in a decrease in feed efficiency (Figure 2.2).  
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Figure 2.1 Interaction between CTSZ and β2 integrin in a Dendritic Cell: A. In an immature, unstimulated dendritic cell, CTSZ is located in the 
perinuclear region and the β2 integrin exists in its low-affinity form. B. Upon cellular stimulation via an antigen, CTSZ migrates to the cellular 
membrane and commences cleavage of the carboxyterminal amino acids from the β2 subunit. C. Cleavage of the four carboxyterminal amino acids 
allows the β2 integrin to convert to its high-affinity form. As the dendritic cell matures, CTSZ migrates back to the perinuclear region. The fully 
matured dendritic celll is then able to interact with a T-lymphocyte via an interaction between the high-affinity β2 integrin on the dendritic cell and inter-
cellular adhesion molecule-1 on the T-lymphocyte. This interaction leads to the proliferation of T-lymphocytes required to initiate a strong immune 
response [177, 180]. 
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Figure 2.2 Effect of leptin on MC3R/MC4R activation: Leptin, released by adipose tissues 
crosses the blood/brain barrier where it binds the leptin receptor expressed on melanocortin 
neurons. This results in an increase in the expression of POMC and the subsequent release of 
MSH, an agonistic ligand of MC3R and MC4R. Activation of MC3R results in an increase in feed 
efficiency while activation of MC4R results in a decrease in food intake. Figure from Melanocortins 
and body weight: a tale of two receptors by Cummings and Schwartz [206].  
 
A study of HIV-infected individuals in Soweto found that there was a decreasing risk of 
both TB morbidity and mortality with an increasing BMI, showing a dose-response effect 
[206]. These findings are also supported by a study of diabetic individuals conducted in 
2007. Leung et al. [207] reported that diabetic individuals falling into either the overweight 
or obese BMI range had a protective effect against TB infection showing a strong linear 
dose-response relationship where for every unit change above a BMI of 18.5, there was a 
10% reduction in risk of developing active TB. An increased BMI typically means an 
increase in fat stores with a corresponding increase in circulating levels of leptin. The 
increased leptin levels may result in increased activation of the MC3R leading to a 
stronger host immune response to infection.  
MC3R is typically studied in combination with the melanocortin 4 receptor (MC4R) as 
these two genes have been found to work closely, but not redundantly with each other and 
both have been previously linked to obesity. 
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2.3 MC4R 
The MC4R gene is found on chromosome 18q22 and encodes a 322 amino acid protein 
which is expressed in the brain, autonomic nervous system and the spinal cord [188, 208]. 
MC4R has shown an association to BMI which measures an individual’s level of adiposity 
and variants in this gene show an association with early onset obesity [201, 209]. Like 
MC3R, the melanocortin 4 receptor protein (MC4R) transmits its signal through regulating 
the intracellular concentration of cyclic adenine monophosphate (cAMP) by increasing 
levels of adenylyl cyclase upon activation via binding of α- and β-MSH and to a lesser 
extent γ-MSH [188, 210]. The role of this gene in obesity has been extensively studied 
[198, 200, 201, 204, 211, 212]. A number of studies which, combined, screened 2 600 
subjects led to the identification of 46 polymorphisms in MC4R found to be associated to 
obesity [213]. The activation of MC4R leads to a reduction in food intake (Figure 2.2) and 
in mice, the homozygous deletion of the gene results in an obese phenotype [213, 214]. 
MC4R is able to regulate food intake by producing a satiety signal after interaction with α-
MSH (MC4R agonist) or an orexigenic signal after interaction with agouti-related protein 
[214, 215]. The exacerbated obesity seen in mice lacking both MC3R and MC4R suggest 
that these two genes perform non-redundant functions. The obesity caused by the 
increase in food intake seen in MC4R knockout mutants is exacerbated by the increase in 
feed efficiency caused by the lack of MC3R.  
Not only is the prevalence of communicable diseases increasing in Africa, there is also a 
global trend for rising prevalence of non-communicable diseases, like diabetes [216]. It 
has been projected that the largest increase will occur mainly in Asia and Africa. Currently, 
70% of individuals with diabetes mellitus (DM) are living in developing countries and much 
evidence exists which supports a link between DM and an increased risk of developing TB 
[216]. A detailed review of 13 studies investigating such an association found that 
regardless of the study design, geographical region or background TB incidence, 
individuals with DM were three times as likely to develop active TB compared to those 
without DM [217]. SNPs in MC4R have also been associated with an increased risk of 
developing diabetes and this association was more evident in women than men [209, 218]. 
2.4 South Africa 
A major obstacle to genetic research is that frequently a gene or variant within a gene is 
found to be associated in one population but not in another. Inconsistencies like this may 
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be explained through the knowledge that with complex diseases, environmental factors 
can influence disease development while genetic factors can influence an individual’s 
susceptibility. Different environmental factors may cause a genetic variant to have a larger 
or smaller affect in one population than in another. The complex ancestry of the Coloured 
population of South Africa (SAC) provides researchers a unique opportunity to study 
complex diseases like TB. The SAC population has a complex history of admixture 
receiving genetic input from Khoisan, South East Asian, Bantu-speaking and European 
antecedents [219]. While the possibility of population stratification can be problematic 
when performing case-control association studies, studies have shown that the SAC 
population, with its wide range of genetic input, currently represents a relatively 
homogenous population [108].  
2.5 Summary  
Due to prevalence of TB in Southern Africa and the rise of non-communicable diseases 
like DM in the developing world, it is imperative that further research is conducted 
investigating the impact of both human genetics and proper nutrition on TB susceptibility. 
Using samples from the SAC population, TB researchers have a unique opportunity to 
study TB infection and the role of host genetics in an admixed population.  
2.6 Aims 
The aim of this study was two-fold.  
a)      Initially, investigations were made to identify any significant association with TB 
susceptibility and selected polymorphisms in CTSZ, MC3R and MC4R in the 
SAC population.  
b)      Secondly, functional analysis was performed in an attempt to provide motivation 
for future studies to determine the role of host metabolism and nutritional status 
on the impact of development of active TB disease.  
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3.1 Study Participants 
Samples were collected from Ravensmead/Uitsig and surrounding suburbs in metropolitan 
Cape Town in the Western Cape province of South Africa. This area was selected due to 
the high incidence of TB and low prevalence of HIV infection [108]. Previous studies have 
found no significant stratification within this population [108]. Ethics approval for this study 
was obtained from the Institutional Ethics Committee (Stellenbosch University, Ethics 
Number 95/072 and Amendments). 
For each gene, a case/control study was performed. The total number of participants in 
each study can be found in Table 3.1. 
Table 3.1 Sample Sizes for each case-control study 
Gene Cases Controls 
CTSZ 410 301 
MC3R 540 541 
MC4R 510 487 
The variation in sample number for each study is a result of the studies occurring 
separately. Samples for the CTSZ investigation were selected by identifying the overlap 
between the investigation of MC3R performed in this study and a previous case-control 
study which also investigated CTSZ (M Möller: unpublished results). This previous study 
was performed in the same SAC population but had not genotyped rs34069356.  The 
same samples used in the MC3R study were selected for use in the MC4R study however 
due to sample exhaustion not all samples were available analysis. Case samples 
consisted of affected individuals belonging to one of two groups: Active TB patients 
(bacteriologically confirmed TB with clinical symptoms) or previous TB patients (previously 
received treatment and had no clinical symptoms at time of sampling). The control 
samples were collected from individuals residing in the same community, living under 
similar conditions including socio-economic status and availability of healthcare facilities, 
who were healthy at the time of sampling. Subjects used in this study were HIV-negative 
and unrelated. Control samples were obtained from individuals who were above the age of 
16 years to ensure a high probability of exposure to M. tuberculosis. Age and gender 
matching was not performed between cases and controls. 
3.2 DNA Samples 
DNA was purified from whole blood using Illustra DNA Extraction Kit BACC3 (GE 
Healthcare, Waukesha, WI, USA) according to the manufacturer’s instructions. The 
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concentrations of DNA samples were determined using a NanoDrop®ND-1000 
Spectrophotometer and the NanoDrop® v3.0.1 Software (Thermo Fisher Scientific, Boston, 
MA, USA). Isolated genomic DNA was diluted in H2O to a final concentration of 100 ng/μl 
and stored at -20°C.  
For the CTSZ and MC4R case-control studies, whole-genome amplified DNA was used. In 
whole genome amplification (WGA), an identical copy of a DNA sample is generated that 
is indistinguishable in sequence but has a much higher concentration than the original 
sample [220].The use of WGA is ideal when DNA samples are limited and when multiple 
genes are being investigated. One reaction can generate micrograms of DNA from 
nanograms of starting material with an average product length of over 10 kb [220]. The 
DNA is replicated extremely accurately due to the use of proofreading 3’ – 5’ exonuclease 
activity of DNA polymerase [220]. An unrelated group of samples was amplified using the 
Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare) according to the 
manufacturer’s instructions. One microliter of DNA was mixed with 9 µl of Sample Buffer 
containing random hexamers which bind non-specifically to the single stranded DNA. The 
reaction mixture was denatured for 3 minutes at 95°C [220]. Following denaturation, 9 µl of 
master mix containing additional random hexamers, nucleotides, salts and buffers was 
added to the denatured DNA and samples were incubated in an isothermal reaction at 
30°C for 1.5 hour to allow for DNA replication. Finally, samples were heated to 65°C for 10 
minutes to terminate the reaction [220].  
3.3 Primer Design  
DNAman v4.1 (Lynnon Corporation, Quebec, Canada) was used to design primers with 
similar melting temperatures, GC content and lacking complementarity. The sequences of 
all primers used in this study can be found in Table 3.2. Primers were made by IDT (San 
Jose, USA). 
3.4 Genotyping Methods 
3.4.1 TaqMan 
TaqMan combines polymerase chain reaction (PCR) amplification and detection into a 
single step by using fluorogenic probes in the 5` nuclease assay [221]. The 5’ nuclease 
assay was originally described by Holland et al. [221]. The introduction of PCR meant the 
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introduction of a DNA amplification technique that is not only both powerful and sensitive 
but also has a wide range of applications [221]. The use of Thermus aquaticus (Taq) DNA 
polymerase improved both the yield and specificity of the PCR product and Holland et al. 
[221] used this enzyme to develop a method where amplification and detection could be 
combined into a single step. With a biallelic system, fluorogenic probes (each specific for a 
particular allele) are included in the PCR reaction [222]. Following PCR, fluorescence 
measurements are taken of each sample and computer software automatically calls each 
of the genotypes. Results typically show 4 distinct clusters for allele 1 homozygotes, allele 
2 homozygotes, heterozygotes and samples which exhibited no amplification as can be 
seen in Figure 3.1 [222]. 
 
Figure 3.1: Allelic Discrimination Using TaqMan: The first of three calculations made by the 
software involves determining the contribution of each individual dye to the measured fluorescence 
spectrum. Next, these results are normalized against negative control samples run on the same 
reaction. From this an individual score for allele one and allele two are determined then the final 
step involves normalizing the extent of the reaction to a blank, also run on the same plate (From 
Applied Biosystems 7900HT Fast Real-Time PCR System Allelic Discrimination Getting Started 
Guide). 
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Table 3.2 Primer Sequences for all studies 
Gene Study Primer Name Application Sequence (5` - 3`) 
CTSZ 
CTSZ1 Forward PCR/Sequencing CTGACGGCAGCAAGGGGAGC 
CTSZ1 Reverse PCR/Sequencing TCCCTCCCTCCCCCACCCTT 
MC3R 
 
MC3R Upstream Forward PCR/Sequencing/Tetra-Primer ARMS CTTGCTCACCACTGTATTTCCT 
MC3R Upstream Reverse PCR/Sequencing AAGCATTCATTGCTGTCAGAAG 
MC3R Exon Forward PCR/Sequencing GAATGAGCATCCAAAAGACG 
MC3R Exon Reverse PCR/Sequencing CTGCATCCTATCCCAAGTTCAT 
SNP (-373) Forward Tetra-Primer ARMS TGTCTTGCCATGAAAAGAGTTT 
SNP (-373) Reverse Tetra-Primer ARMS CACCGGCTGCTACAGTCAC 
Tubulin Forward Primera Real-time PCR GCCAGATGCCAAGTGAC 
Tubulin Reverse Primera Real-time PCR CTGAAGAAGGTGTTGAAGGAAT 
MC3R Forward Primera Real-time PCR CGTGGTGTTCATCGTCTAC 
MC3R Reverse Primera Real-time PCR AGAACATGGTGATGAGGC 
MC4R 
MC4R Forward PCR/Sequencing ATGCGATGAGCCCCACTGTC 
MC4R Reverse PCR AGCTGCCTTTTCCCACCCAC 
Seq Primer 2a Sequencing GCAAAATATTCAGAAACTT 
Seq Primer 3 Sequencing GACTTCAGGAGCTTCTGC 
Seq Primer 4 Sequencing GCCTCACAACTTTCAGAC 
Seq Primer 5 Sequencing CTGTAGCTCCTTGCTTGC 
Seq Primer 6 Sequencing CCTCTGATTTATGCACTCCGG 
a
 Primers designed and prepared by Roche
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TaqMan was used to genotype 1 SNP in CTSZ and 3 SNPs in MC4R. The reaction was 
set up according to an adjusted TaqMan protocol developed and verified in house. The 
manufacturer’s instructions (Applied Biosytems®, Foster City, USA) require 1 to 20 ng of 
purified genomic DNA to be used in the reaction, however, in both the CTSZ and MC4R 
studies, 100 ng of WGA-DNA was used instead. Using the Eppendorf EpMotion® 5070, 
TaqMan plates were prepared with 5 µL of 20 ng/µL WGA DNA, 2.5 µL Master Mix, 0.0625 
µL SNP specific TaqMan assay and 2.4375 µL ddH2O samples for a final reaction volume 
of 10 µL. PCR was carried out on a GeneAMP® PCR System 9700 (Applied Biosystems) 
and the protocol was as follows: 95°C for 10 minutes, 45 cycles of 95°C for 10 seconds 
then 60°C for 1 minute, followed by a hold at 10°C. Immediately after amplification, 
fluorescence of each reaction was measured on the 7900HT Fast Real-Time PCR System 
(Applied Biosystems). Sequence Detection Systems v2.3 software (Applied Biosystems) 
was used to automatically call genotypes.  
3.4.2 Direct Sequencing 
3.4.2.1 MC3R Initial Screening 
To determine which MC3R polymorphisms were present in the SAC population, the single 
exon of MC3R and 1000 bp upstream of the gene were sequenced in 10 cases and 10 
controls. These two regions were first amplified by PCR. Each reaction contained 100 ng 
of genomic DNA, 2.5 μl of 10X Reaction Buffer containing 15mM MgCl2 (Southern Cross 
Biotechnologies, Cape Town, South Africa), 1 μl of 2.5 mM dNTPs (Bioline, London, UK), 
1 µl each of forward and reverse primers (all primers used in this study were of a 
concentration of 10 nM) (Integrated DNA Technologies, Coralville, USA) and 0.075 μl of 
Super-Therm Gold DNA polymerase (Southern Cross Biotechnologies). Reactions were 
made up to a volume of 25 µl with sterile ddH2O. MC3R Upstream Forward and MC3R 
Upstream Reverse primers were used to amplify the upstream region and the exon was 
amplified by MC3R Forward and MC3R Reverse primers (Table 3.2). An Eppendorf 
Mastercycler® PCR System (Eppendorf, Hamburg, Germany) was used for the following 
cycling program: 10 minutes of denaturation at 95°C followed by 30 cycles of 1 minute at 
94°C, 1 minute at 54.1°C and 2 minutes at 72°C. The reaction was terminated at 72°C for 
10 minutes. To control for contamination, a negative control sample containing only master 
mix was included in every run.  
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Successful amplification was verified via agarose gel electrophoresis. A 1% agarose 
sodium borate (SB) gel was prepared with 1 g of agarose (Seakem, Rockland, USA), 100 
ml of 1X SB buffer and 0.5 μl of 10 mg/ml ethidium bromide (Invitrogen, San Diego USA). 
Five microliters of PCR product together with 5 μl of 2X loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in water) were loaded onto the 
gel. Five microliters of a 100 bp DNA ladder (Thermo Fisher Scientific) was 
electrophoresed with the samples as a molecular weight marker. The samples were run for 
1 hour at 150 V and the gel was photographed with UV light using G:Box (Syngene, 
Frederick, USA).  
Prior to sequencing, PCR products were purified using ExoSAP-IT clean up (Affymetrix, 
Santa Clara, USA) according to the manufacturer’s instructions. Five microliters of 
amplicon was mixed with 2 μl ExoSAP-IT and the sample was incubated in an Eppendorf 
Mastercycler®ep for 37°C for 15 minutes to degrade remaining primers and nucleotides. 
This was followed by 80°C for 15 minutes to inactivate ExoSAP-IT, 2 minute incubation at 
5°C and a 15°C hold. The fragment was sequenced in both forward and reverse direction 
by the Central Analytical Facility (CAF) (Stellenbosch, South Africa). Sequencing data was 
analyzed using Sequencher v4.10 (Gene Codes Corporation, Ann Arbour, USA). To 
determine which polymorphisms had been previously reported, the sequence containing 
the polymorphism was aligned to the human genome using Blat 
(http://genome.ucsc.edu/cgi-bin/hgBlat). If a polymorphism had been previously reported 
Blat listed the rs number (a unique record identifier assigned by Single Nucleotide 
Polymorphism Database (dbSNP)). This database was established by the National Human 
Genome Research Institute and The National Center for Biotechnology Information 
(NCBI). SNPs selected for genotyping can be found in Table 3.3.  
Table 3.3 SNPs genotyped in CTSZ , MC3R and MC4R 
GENE rs Number Position Genotyping Method 
CTSZ rs34069356 Exon 6, missense Taqman 
MC3R 
rs72650656 Promoter Sequencing 
rs6127698 Promoter Sequencing 
rs11575886 Promoter Sequencing 
rs72650657 Promoter Sequencing 
rs72650658 Promoter Sequencing 
rs3827103 Exon 1, missense Sequencing 
MC4R 
rs11872992 Promoter Taqman 
rs8087522 Promoter Taqman 
rs34114122 5` UTRa Taqman 
a Untranslated Region 
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The single SNP selected for the investigation of CTSZ in this study was the same SNP 
identified by Cooke et al. [82] which showed evidence of association to TB susceptibility. 
SNPs were selected for the MC3R study if they were identified in the SAC population 
during the initial screening. A similar process was used for the selection of MC4R SNPs, 
with the three SNPs showing the highest prevalence in the SAC population being selected 
for genotyping. 
3.4.2.2 MC3R Genotyping 
An unrelated case-control study was performed by genotyping TB case and control 
samples via direct sequencing as described in Section 3.4.2.1. Purification of PCR product 
was performed by CAF. Variations detected in the initial screen were automatically 
genotyped in all the samples using the software SGcaller developed by Christian-
Albrechts-University (Kiel, Germany) [223]. 
3.4.2.3 MC4R Initial Screening 
To determine which MC4R polymorphisms were present in the SAC population, the single 
exon of MC4R and 1000 bp upstream of the gene were sequenced in 10 cases and 10 
controls. One 3300 bp fragment was amplified via PCR. Each reaction contained 100 ng of 
genomic DNA, 2.5 μl of 10X reaction buffer containing 15mM MgCl2 (Southern Cross 
Biotechnologies), 1 μl of 2.5 mM dNTPs (Bioline), 1 µl of MC4R Forward primer, 1 µl 
MC4R Reverse primer (Integrated DNA Technologies) and 0.075 μl of Super-Therm Gold 
DNA polymerase (Southern Cross Biotechnologies). Reactions were made up to a volume 
of 25 µl with ddH2O. An Eppendorf Mastercycler PCR System was used for the following 
cycling program: 10 minutes of denaturation at 95°C followed by 40 cycles of 1 minute at 
94°C, 2 minute at 65°C and 2.5 minutes at 72°C. The reaction was terminated at 72°C for 
10 minutes. To control for contamination, a negative control sample containing only master 
mix was included in every run. The remainder of the screen was performed as described in 
Section 3.4.2.1. Polymorphisms selected for genotyping can be found in Table 3.3. 
3.4.3 Tetra-primer Amplification Refractory Mutation System  
Genotyping of the MC3R SNP associated with TB susceptibility in volunteer blood samples 
was performed by Tetra-primer Amplification Refractory Mutation System (ARMS) as 
previously described by Ye et al. [223]. Tetra-primer ARMS is a reliable method which 
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genotypes a sample in a single PCR reaction. The tetra-primer ARMS concept is depicted 
in Figure 3.2. Previous studies have shown that this method is robust and reproducible 
using different thermal cyclers in different laboratories with fully concordant results [224]. 
Each reaction contained 100 ng of genomic DNA, 2.5 μl of 10X reaction buffer containing 
1.5 mM MgCl2 (Southern Cross Biotechnologies), 1 μl of 2.5 mM dNTPs (Bioline), 0.5 μl of 
MC3R Upstream Forward primer, 0.5 μl MC3R Upstream Reverse primer, 4 μl of SNP(-
373) Forward primer, 2 μl of SNP(-373) Reverse primer, 0.05 μl of Super-Therm Gold DNA 
polymerase (Southern Cross Biotechnologies). Reactions were made up to a volume of 25 
µl with sterile ddH2O. An Eppendorf Mastercycler PCR System was used for the following 
cycling program: 10 minutes of denaturation at 95°C followed by 30 cycles of 1 minute at 
94°C, 1 minute at 58°C and 1 minute at 72°C. The reaction was terminated at 72°C for 10 
minutes. To control for contamination, a negative control sample containing only master 
mix was included in every run. A positive control for each genotype was run with every 
reaction. Gel electrophoresis was performed as described in Section 3.4.2.1. 
3.5 Statistical Analysis 
Epi InfoTM (CDC, Atlanta, USA) was used to determine the sample size required to 
generate results with 80% power and a 95% confidence interval (CI). Assuming an allele 
frequency of at least 5%, a sample size of approximately 500 cases and 500 controls was 
selected for all case-control studies to enable the detection of an odds ratio (OR) = 2.0. 
For each SNP that was genotyped, Hardy-Weinberg equilibrium (HWE) was assessed. 
Prism v4.02 (GraphicPad Software, La Jolla, USA) was used to calculate the OR, 95% CI 
and p-values for the single point analysis. It was used to determine the mean and standard 
deviation of results obtained from functional analysis. Genotypic distribution between 
cases and controls was calculated by either χ2 test or Fisher’s exact test. For SNPs where 
all 3 genotypes were represented in both cases and controls, a p-value was determined 
using the χ2 test. The Fisher’s exact test was used when the allelic frequency was low 
resulting in at least one of the three possible genotypes being absent in either the cases or 
controls. A significant p-value was defined as < 0.05. Haploview v4.1 (Broad Institute, 
Cambridge, USA) was used to evaluate differences in haplotypes between cases and 
controls and assess which SNPs were in LD. Permutation testing was performed to 
determine if the observed difference in allele frequency was greater than could have 
occurred by chance [108] . 
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Figure 3.2 Concept of Tetra-
primer ARMS: One primer set 
(the outer set) will be amplified 
in every reaction to act as a 
positive control to ensure 
success of the reaction. These 
outer primers are designed in 
such a way that they are 
asymmetrically located around 
the SNP to ensure that the 
allele specific amplicons differ 
enough in size to be easily 
separated by gel 
electrophoresis [222]. The 
nested primer set is allele 
specific and will amplify 
fragments only if a particular 
allele is present. To enhance 
allele-specificity, a deliberate 
mismatch at position -3 bases 
from the 3’ end is incorporated 
into these primers. The 
presence of a DNA fragment on 
an agarose gel will indicate 
which base is present at the 
locus. 
 
3.6 Functional Analysis 
3.6.1 BCG Cultures and Stocks 
Five milliliters of starter culture of BCG obtained in the division of molecular biochemistry 
and human genetics was inoculated into 35 ml of Middlebrook 7H9 broth (BD Scientific, 
Sparks, USA) enriched with 0.2% glycerol, 0.1% Tween80 and 10% Middlebrook oleic-
albumin-dextrose-catalase (OADC) (BD Scientific) and cultured until optical density (OD) 
reached between 0.8 and 0.9 as measured at 600 nm. Thirty milliliters of BCG culture was 
transferred to 50 ml Falcon tube and centrifuged at 3000 rpm for 5 min at room 
temperature (RT). The supernatant was discarded and the pellet was resuspended in 20 
ml  sterile 15% glycerol. Stocks were prepared by aliquoting 1 ml  of resuspended culture 
into 1.5 ml centrifuge tubes which were stored at -80oC for future use. Bacterial 
concentrations were ascertained by determining the number of colony forming units per 
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milliliter by plating 100 µl aliquots of a serial dilution of 100%, 10%, 1% and 0.1% BCG 
stock on agar plates. Plates were prepared according to the manufacturer’s instructions. 
Each plate contained 50 ml of Middlebrook 7H11 Agar enriched with 0.5% glycerol and 
10% Middlebrook OADC (BD Scientific). Plates were incubated at 37oC for 2.5 weeks 
before determining the colony forming units per milliliter stock solution.  
3.6.2 Culturing Monocyte-Derived Macrophages 
Monocyte-derived macrophages (MDMs) were isolated from peripheral blood mononuclear 
cells (PBMCs) obtained from fresh human blood. Peripheral venous blood samples were 
collected from healthy adult volunteers using Vacutainers containing EDTA and DNA was 
isolated as previously described (Section 3.2). Volunteers were genotyped using tetra-
primer ARMS (Section 3.4.3) for the MC3R promoter SNP found to be associated with TB 
susceptibility. Individuals homozygous for either the T or G allele were then sequenced by 
the CAF to detect any additional polymorphisms either in the single exon of the gene or up 
to 1000 bp upstream. Volunteers with no additional polymorphisms in the sequenced 
region were selected for functional analysis. Two volunteers with the GG genotype and 
one volunteer with the TT genotype were selected. Forty milliliters of peripheral blood was 
collected into heparinised tubes (BD Scientific) and PBMCs were isolated by Ficoll-
Histopaqe density gradient centrifugation. Twenty milliliters of heparinised fresh whole 
blood was made up to a final volume of 35 ml with GIBCO® GlutaMAX™ media 
(Invitrogen) and pipetted over 15 ml of Histopaque (Sigma-Alrich, St. Louis, USA). 
Samples were centrifuged at 400g for 25 minutes at RT with no brake or accelerator using 
an Eppendorf Centrifuge 5810R. Mononuclear cells were harvested with a pipette and 
washed twice with GIBCO® GlutaMAX™ media. Cells were pelleted between washes by 
centrifugation at 250g for 5 minutes. After the final wash the cell pellet was resuspended in 
2 ml GIBCO® GlutaMAX™ media enriched with 10% Human AB Serum (Sigma-Aldrich) 
referred to henceforth as complete media.  
PBMCs were seeded into 6-well tissue culture plates (Nunc, Rochester, USA) at 1 x 107 
cells/ml and were incubated in an autoflow CO2 water jacketed incubator (Thermofisher 
Scientific) at 37oC containing a humidified atmosphere and 5% CO2 for 16h to allow 
mononuclear cells to adhere to the plate. Following the incubation period the conditioned 
media was removed and centrifuged at 700g for 5 minutes to remove all non-adherent 
cells and cellular debris. This supernatant was transferred to a fresh 15 ml centrifuge tube. 
Adherent cells were then stimulated with BCG at a multiplicity of infection of 2 for 4 hours. 
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Following stimulation, medium was removed and wells were washed 3 times with GIBCO® 
GlutaMAX™ medium to remove all non-phagocytosed bacteria. Complete medium 
enriched with 10% conditioned medium was added at 2 ml per well and cells were cultured 
for 6 days. Following the incubation period, RNA was extracted. 
3.6.3 Analysis of RNA transcript levels 
The use of reverse transcription of RNA into cDNA followed by quantitative PCR (qPCR) is 
a powerful method used to detect minute levels of RNA transcripts [225]. Using qPCR, 
RNA transcript levels can be determined using absolute quantification which requires a 
calibration curve, meticulously validated methodology, identical amplification efficiencies 
for target and control genes and must be run on the same LightCycler® System [226]. An 
alternative method of RNA quantification normalizes the target gene against an 
endogenous standard and is currently the recommended method for analysis of gene 
expression. In this method, the target gene expression is normalized against the 
expression of a reference gene which is typically a non-regulated reference gene or a 
housekeeping gene which is present in all nucleated cell types [226]. In this study, MC3R 
gene expression was normalized against the expression of the housekeeping gene α-
tubulin as has been previously used in studies investigating MC3R protein expression in 
macrophages [190].  
Following the qPCR reaction, two main mathematical models can be applied to analyze 
the results. Both will be discussed below. 
3.6.3.1 RNA extraction 
RNA was extracted using TRIzol® reagent (Invitrogen) according to the manufacturer’s 
instructions. Following a 6 day culture, cells were washed with fresh media to remove any 
cellular debris. Cells were lysed with 1 ml  of TRIzol and cells were removed using a 
rubber policeman and lysate was transferred to a 1.5 ml  centrifuge tube. Lysates were 
incubated at RT for 5 minutes after which 200 µL of chloroform was added and samples 
were vortexed. Samples were incubated at RT for 5 minutes followed by centrifugation for 
15 minutes at 12 000g at 4°C. Immediately following centrifugation, the top clear organic 
phase was removed and added to 500 µl ice cold isopropanol in a new 1.5 ml  centrifuge 
tube. Samples were vortexed and incubated for 15 minutes at RT then centrifuged for 15 
minutes at 12 000g at 4°C. The supernatant was discarded and the RNA pellet was 
washed with 1 ml  RNase free 70% ethanol. Samples were vortexed and centrifuged for 5 
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minutes at 7500g at 4°C. The supernatant was removed and pellets were allowed to air 
dry at RT. Once all ethanol had evaporated, RNA pellets were resuspended in 20 µl 
RNase free water and the OD was measured using a NanoDrop®ND-1000 
Spectrophotometer and the NanoDrop® v3.0.1 Software (Thermo Fisher Scientific).  
3.6.3.2 RT-PCR 
Purified RNA was reverse transcribed to cDNA using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche, Basel, Switzerland) according to the manufacturer’s instructions. All 
reagents were centrifuged before use and the entire reaction was set up on ice. One 
microgram of RNA was added to 2 µl of Random Hexamer Primer and the volume was 
made up to 13 µl with PCR-grade water. Samples were denatured by incubation for 10 
minutes at 65°C in an Eppendorf Mastercycler PCR System. Samples were immediately 
cooled on ice. To each sample, 4 µl of Transcriptor Reverse Transcriptase Reaction buffer, 
0.5 µl Protector RNase Inhibitor, 2 µl of dNTPs (10mM) and 0.5 µl of Transcriptor Reverse 
Transcriptase was added to each sample. All samples were incubated for 10 minutes at 
25oC followed by second incubation for 30 minutes at 55°C. The reaction was terminated 
with a 5 minute incubation at 85°C. The concentration of cDNA was determined using a 
NanoDrop®ND-1000 Spectrophotometer and the NanoDrop® v3.0.1 Software (Thermo 
Fisher Scientific). 
3.6.3.3 qPCR 
Prior to the analysis of the RNA transcript levels, the MC3R and α-tubulin assays were 
optimized to have an assay efficiency between 80 and 120%. Assays were optimized 
using a standard curve containing the following dilution series: 100 ng, 75 ng, 50 ng, 25 
ng, 12.5 ng, 10 ng, 6.25 ng and 0 ng. MC3R RNA transcripts were quantified using 
LightCycler® FastStart DNA Master SYBR Green I Kit (Roche) according to the 
manufacturers’ instructions. The reaction was repeated with primers specific for α-tubulin 
to act as an internal control. To measure MC3R transcript levels, a 62 bp fragment of the 
transcript was amplified with 1 µl of each PCR primer (0.5 µM), 2 µl dNTPs, 1.5 µl MgCl2, 
2.5 µl LightCycler® FastStart DNA Master SYBR Green I (Roche) and 5 µl PCR grade H2O 
which were mixed and transferred to a pre-cooled LightCycler® Capillary (Roche). To each 
capillary, 100 ng cDNA was added and each capillary was sealed with a stopper. 
Capillaries were centrifuged at 0.7g prior to being transferred to the LightCycler® Sample 
Carousel (Roche) and placed in the LightCycler® instrument. A LightCycler® 1.5 (Roche) 
was used for the following cycling program: 15 minutes of enzyme activation at 95°C 
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followed by 50 cycles of 15 seconds at 95°C, 15 seconds at 50°C and 8 seconds at 72°C. 
Melt curve analysis was performed using the following reaction conditions: an incubation of 
0s at 95°C, a 15s incubation at 65°C with temperature increase up to 95°C at a ramp rate 
of 0.1°C/second. The reaction was terminated at 40°C for 10 minutes. To amplify a 61 bp 
fragment of the α-tubulin transcript, 2 µl of each PCR Primer (0.5 µM), 2 µl dNTPs, 1.5 µl 
MgCl2, 2 µl LightCycler
® FastStart DNA Master SYBR Green I (Roche) and 8.5 µl PCR 
grade H2O were mixed and transferred to a pre-cooled LightCycler
® Capillary (Roche). To 
each capillary, 65 ng cDNA was added and each capillary was sealed with a stopper. 
Capillaries were centrifuged at 0.7g prior to being transferred to the LightCycler® Sample 
Carousel (Roche) and placed in the LightCycler® instrument. A LightCycler® 1.5 (Roche) 
was used for the following cycling program: 15 minutes of enzyme activation at 95°C 
followed by 40 cycles of 15s at 95°C, 15s at 61°C and 8s at 72°C. Melting curve analysis 
was performed using the following reaction conditions: an incubation of 0s at 95°C, 15s 
incubation at 65°C with temperature increase up to 95°C at a ramp rate of 0.1°C/second. 
The reaction was terminated at 40°C for 10 minutes. To ensure success of the reactions, a 
positive control sample was included in every run. Contamination was controlled for by the 
inclusion of a negative control sample containing only master mix in every run.  
3.6.3.4 Livak Method 
RNA quantification based on the average threshold cycle (Ct) value is performed without 
correction for differences in amplification efficiency. This method assumes that the 
amplification product is less than 150 bp and the primer and Mg2+ concentrations have 
been properly optimized, yielding an assay efficiency close to 1 [227]. With this method the 
equation used to analyze the relative gene expression is: 
PC
ettamount
 2arg      (eq. 1) 
The entire derivation of this equation can be found in a paper published by Livak and 
Schmittgen in 2001 [227]. For this method to be valid the amplification efficiency for the 
target and the reference genes must be approximately equal. A final value of 1 indicates 
there is no change in gene expression while a value of less than one indicates a decrease 
in expression and a value larger than one indicates an increase in expression. 
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3.7.3.5 Pfaffl Method 
The mathematical model developed by Pfaffl allows for differences in the amplification 
efficiency to be incorporated into the RNA quantification [226]. When a target gene is 
normalized against a single reference gene one uses the equation:  
 
  )(
)(
arg
arg
samplecontrolCP
reference
samplecontrolCP
ett
reference
ett
E
E
ratio



   (eq. 2) 
This ratio compares the change in expression of a target gene in a treated sample 
compared to a control sample versus the change in expression of a reference gene in a 
treated sample compared to a control sample. Etarget and Ereference refer to the 
predetermined amplification efficiency of the target and the reference genes, respectively 
[226]. Amplification efficiencies are calculated from the slope produced by the standard 
curve used during reaction optimization. 
  
 
 
 
 
 
 
 
CHAPTER 4: Results 
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4.1 Introduction 
To investigate the association of polymorphisms in CTSZ, MC3R and MC4R to TB 
susceptibility, 3 independent case-controls studies were performed using an SAC 
population previously shown to be free of population stratification [82]. A number of SNPs 
which were all found to be in HWE were selected for genotyping (Table 3.3). Haplotype 
analysis was performed on each gene for the SNPs genotyped. Although CTSZ and 
MC3R are within close proximity on chromosome 20, the two genes were determined to be 
in linkage equilibrium and were subsequently analyzed separately. Following the detection 
of a statistically significant association between a promoter polymorphism in MC3R, 
functional analysis was performed to investigate the influence of this SNP on gene 
expression when stimulated with BCG. 
4.2 CTSZ 
4.2.1 Single Point Analysis  
For CTSZ, the same SNP reported by Cooke et al. [82] to be associated in West Africa 
(rs34069356) also showed evidence of disease association in an SAC population with the 
AA genotype being over represented in TB patients (genotypic OR 0.28(0.17-0.45); p 
<0.0001) (Table 4.1). This remained significant even after stringent Bonferroni correction 
for multiple testing. This SNP is located within the last (sixth) exon of the gene and is a 
missense mutation resulting in an amino acid change from alanine to threonine.  
4.2.2 Haplotype Analysis 
Four SNPs from a previous study investigating the association of CTSZ to TB susceptibility 
in the SAC population, viz. rs448943, rs10369, rs13720 and rs3787492, were included in 
the haplotype analysis of CTSZ (Adams, submitted) (Table 4.2). The SNPs rs34069356 
and rs3787492 was excluded from the analysis since their allele frequencies were below 
1% (Figure 4.1). Three of the markers previously genotyped in CTSZ, rs448943, rs10369 
and rs13720, were identified as a single block. Following haplotype analysis there did not 
appear to be any association with TB. These results were repeated when analyzed with 
the Cocaphase program in the UNPHASED suite (LITBIO, Italy). 
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Table 4.1 Single Point Analysis of CTSZ 
a
 number of individuals investigated 
b
Allele 1 is the minor allele 
c
 p-value based on a genotype-based Fisher exact test 
d
odd ratio calculated by Prism 
 
Table 4.2 Haplotype analysis of CTSZ 
GENE Haplotype 
Haplotype Frequency 
χ2 P value P valuepermutation
b OR (95% CI) 
Cases Controls 
CTSZ 
Blocka: rs448943 – rs10369 – rs13720  
N1 A-C-A 0.337 0.342 0.05 0.8228 0.9999 1 
N2 G-C-A 0.258 0.255 0.02 0.8894 1.0000 0.95 (0.74 – 1.22) 
N3 G-T-A 0.242 0.202 3.29 0.0697 0.3706 1.19 (0.92 – 1.55) 
N4 A-C-G 0.163 0.199 3.12 0.0775 0.4003 0.92 (0.70 – 1.20) 
a The order of the SNPS in detected haplotype block corresponds to Figure 4.1 
b Permutation test p values were calculated from 10 000 permutations in Haploview. 
  Genotype Frequency 
 
Genotypic 
 
Allelic 
SNP Group Na 1b1 12 22 
 
p-value c ORd (95% CI) 
 
p-value OR (95% CI) 
CTSZ      
      
rs34069356 A/G 
TB 410 0.00 0.23 0.77 
 
<0.0001  0.28 (0.17 – 0.45) 
 
<0.0001 0.31 (0.19 – 0.49) 
Controls 301 0.00 0.08 0.92 
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Figure 4.1 LD Plots of CTSZ 
SNPs analyzed: LD plot generated 
by Haploview v4.1. r2-values (%) 
are indicated on the squares. The 
colours of the squares represent 
LD strength according to D` values, 
with red being strong and blue 
being weak. Haplotype block is 
outlined in black. CTSZ_34069356 
and CTSZ_3787492 were excluded 
as allele frequencies were less than 
1%. 
 
 
4.3 MC3R 
4.3.1 Single Point Analysis  
One of the SNPs in MC3R, rs6127698, is located 373bp upstream of the start codon and 
showed statistically significant difference in allelic frequency distribution between TB 
patients and controls (Table 4.3). The least common allele, T, was found more frequently 
in controls than in cases, indicating a possible resistance phenotype for the TT genotype. 
This association remained significant after adjusting for multiple testing (p = 0.0039, OR of 
the GG genotype for disease, 1.5 (1.18 – 1.92)).  
 
4.3.2 Haplotype Analysis 
Four of the SNPs in MC3R, viz. rs72650656, rs11575886, rs72650657 and rs72650658, 
were excluded from the analysis since their allele frequencies were below 1%. SNPs 
rs6127698 and rs3827103 in MC3R were grouped as one haplotype block (Figure 4.2). 
Within this block, three haplotypes were identified with haplotype N1 being the most 
frequent (Table 4.4). Haplotype N3 showed a significant association with case-control 
status (p=0.0008) which was observed only 61 out of 10 000 times during permutation 
testing done to correct for multiple testing (Table 4.4). A similar result was found with the 
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Table 4.3 Single Point Analysis of MC3R 
a
 number of individuals investigated 
b
Allele 1 is the minor allele 
c
 p-value based on a genotype-based Fisher exact test 
d
 p-value based on a genotype-based χ
2
 test
 
e
odd ratio calculated by Prism 
   Genotype Frequency Genotypic Allelic 
SNP Group Na 1b1 12 22 p-value ORe (95% CI) p-value OR (95% CI) 
MC3R          
rs72650656 G/C 
TB 534 0.00 0.01 0.99 1.0000c 0.88 (0.31 – 2.45) 0.9854 0.88 (0.32 – 2.44) 
Controls 529 0.00 0.01 0.99     
rs6127698 T/G 
TB 540 0.07 0.32 0.61 0.0039d 1.50 (1.18 – 1.92) 0.0012 1.39 (1.14 – 1.68) 
Controls 540 0.08 0.39 0.51     
rs11575886 C/T 
TB 537 0.01 0.06 0.93 0.1240c 1.19 (0.74 – 1.92) 0.8333 1.08 (0.68 – 1.71) 
Controls 540 0.00 0.07 0.93     
rs72650657 G/C 
TB 537 0.00 0.04 0.96 0.5666c 1.2 (0.69 – 2.15) 0.5892 1.21 (0.69 – 2.12) 
Controls 541 0.00 0.05 0.95     
rs72650658 G/C 
TB 532 0.00 0.02 0.98 0.1767c 0.40 (0.12 – 1.27) 0.1823 0.40 (0.12 – 1.28) 
Controls 530 0.00 0.01 0.99     
rs3827103 G/A 
TB 529 0.14 0.42 0.44 0.1751
d 0.84 (0.66 – 1.07) 0.1056 0.88 (0.72 – 1.03) 
Controls 529 0.10 0.40 0.49     
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Cocaphase program in the UNPHASED suite which also found a significant association 
with the same haplotype in MC3R. 
 
 
Figure 4.2 LD Plots of MC3R SNPs analyzed: LD plot generated by Haploview v4.1. r2-values 
(%) are indicated on the squares. The colours of the squares represent LD strength according to 
D` values, with red being strong and blue being weak. Haplotype block is outlined in black. 
MC3R_rs72650656, MC3R_rs11575886, MC3R_rs72650657 and MC3R_rs72650658, were 
excluded as allele frequencies were less than 1%. 
4.3.3 RNA Transcript Analysis 
Prior to transcript analysis, the assay was optimized using a standard curve to determine 
the assay efficiency for both the target and the reference genes. Assay efficiencies can be 
found in Table 4.5. During assay optimization, varying quantities of cDNA were used to 
select the ideal amount for each the MC3R and α-tubulin assays. Differences in the 
concentrations used for each of the assays can be attributed to differences in the overall 
amount of each gene’s transcript present in the total RNA isolated and differences in 
primer melting temperature. In order to optimize amplification of both assays when run with 
an annealing temperature of 61°C, different amounts of RNA transcript were required for 
each assay. 
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After RNA was isolated as described in Section 3.6.3.1, cDNA was prepared via a reverse 
transcription reaction as described in Section 3.6.3.2. cDNA was subsequently used for a 
qPCR reaction to determine relative gene expression of the MC3R gene normalized 
against the endogenous housekeeping gene (α-tubulin) (Section 3.6.3.3). Each experiment 
was performed in triplicate and each assay was run in duplicate. Melt curve analysis 
indicates a lack of primer dimer in all samples (Figure 4.3). The amplification curves show 
an absence of amplification in the blank suggesting there was no nonspecific amplification 
in the samples (Figure 4.4).  
 
 
Figure 4.3 Melt Curve Analysis: Melt curve analysis was performed with each run to ensure that 
the reaction contained only a single amplicon. All samples showed a single peak indicating that 
samples lacked primer-dimer formation and additional non-specific amplification.  
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Table 4.4 Haplotype analysis of MC3R 
GENE Haplotype 
Haplotype Frequency 
χ2 P value P valuepermutation
b OR (95% CI) 
Cases Controls 
MC3R 
Blocka: rs6127698 – rs3827103  
N1 G-G 0.429 0.403 1.46 0.2272 0.7777 0.95 (0.79 – 1.17) 
N2 G-A 0.3464 0.308 3.41 0.0647 0.3469 1  
N3 T-G 0.225 0.288 11.22 0.0008 0.0061c 0.71 (0.56 – 0.89) 
a The order of the SNPS in detected haplotype block corresponds to Figure 4.2 
b Permutation test p values were calculated from 10 000 permutations in Haploview. 
c p values less than 0.0008 were observed on 61 out of 10 000 occasions (0.61%) during permutation testing. 
 
 
Table 4.5 Assay Efficiency: Efficiencies for each assay was determined based on the slope produced from a standard curve during 
assay optimization.  
Gene Efficiency Value 
Target (MC3R) 1.936 
Reference (α-tubulin) 1.885 
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Figure 4.4 Amplification Curve: The amplification curve indicates that each sample reaction ran to completion and 
the lack of amplification in the negative control sample shows absence of non-specific amplification, the presence of 
which could negatively impact the calculated CT values. 
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4.3.3.1 Livak Method 
The average change in gene expression between macrophages stimulated with BCG and 
not stimulated with BCG was determined. Using the Livak method (equation 1), the 
average change in MC3R gene expression was normalized against the average change in 
α-tubulin expression. The change in gene expression was calculated for each qPCR 
reaction. These results were then analyzed by Prism to determine the mean and the 
standard deviation for each genotype. The results for the analysis using the Livak method 
can be seen in Figure 4.5. While results did not show a statistically significant difference in 
the change in MC3R gene expression between the GG and TT genotypes, both showed 
an upregulation in MC3R gene expression upon stimulation with BCG. The TT genotype 
showed a trend for an even larger increase in MC3R transcription than the GG genotype, 
suggesting that upregulation of this gene may be associated with resistance in TB. 
 
Figure 4.5 Graphic Representation of the change in MC3R gene expression using the Livak 
method: Values were determined for each qPCR run then the average value was taken for each 
genotype. Average values for each genotype are shown with standard deviation. 
4.3.3.2 Pfaffl Method 
Using the Pfaffl method (equation 2), the average change in MC3R gene expression was 
normalized to the average change in α-tubulin expression when stimulated with BCG. 
Efficiency values used in the calculation can be found in Table 4.5. The change in gene 
expression was calculated for each qPCR reaction. These results were then analyzed by 
Prism to determine the mean and the standard deviation for each genotype. Results for 
the analysis using the Pfaffl method can be seen in Figure 4.6. Results of the analysis of 
the change in MC3R gene expression upon stimulation with BCG as determined with the 
Pfaffl method were similar to those obtained by the Livak method. The smaller standard 
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deviation values obtained with the Pfaffl method may be a consequence of the Pfaffl 
method taking into account the differences in amplification efficiency between each assay. 
 
Figure 4.6 Graphic Representation of the change in MC3R gene expression using the Pfaffl 
method: Values were determined for each qPCR run then the average value was taken for each 
genotype. Average values for each genotype are shown with standard deviation. 
4.4 MC4R 
4.4.1 Single Point Analysis 
Two of the SNPs in MC4R, rs11872992 and rs8087522, both located in the upstream 
region of the MC4R gene showed statistically significant differences in allele frequency 
distribution between TB patients and controls (Table 4.6). In both SNPs, the most common 
allele was found more frequently in cases than in controls but this association was not 
seen in the genotypic p-value.  
4.4.2 Haplotype Analysis 
Haplotype analysis of the 3 SNPs analyzed in MC4R identified two SNPs, rs8087522 and 
rs11872992, found to be in LD (Figure 4.7). While there appeared to be a statistically 
significant association between a single haplotype with TB disease, significance was lost 
when corrections were made for multiple testing. 
Figure 4.7 LD Plots of MC4R SNPs 
analyzed: LD plot generated by 
Haploview v4.1. r2-values (%) are 
indicated on the squares. The colours of 
the squares represent LD strength 
according to D` values, with red being 
strong and blue being weak. Haplotype 
block is outlined in black.  
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 Table 4.6 Single Point Analysis of MC4R 
a
 number of individuals investigated 
b
Allele 1 is the minor allele 
c
 p-value based on a genotype-based Fisher exact test 
d
 p-value based on a genotype-based χ
2
 test
 
e
odd ratio calculated by Prism 
 
Table 4.7 Haplotype Analysis of MC4R 
a The order of the SNPS in detected haplotype block corresponds to Figure 4.2 
b Permutation test p values were calculated from 10 000 permutations in Haploview. 
   Genotype Frequency Genotypic Allelic 
SNP Group Na 1b1 12 22 p-value ORe (95% CI) p-value OR (95% CI) 
MC4R          
rs11872992 G/A 
TB 509 0.00 0.10 0.90 0.0689c 1.438 (0.99 – 2.10) 0.0372 1.48 (1.04 – 2.12) 
Controls 487 0.01 0.14 0.85     
rs8087522 G/A 
TB 498 0.18 0.46 0.36 0.0908d 1.344 (1.02 – 1.76) 0.0393 1.21 (1.01 – 1.45) 
Controls 471 0.22 0.49 0.29     
rs34114122 C/A 
TB 510 0.00 0.15 0.85 0.8205c 0.9285 (0.66 – 1.31) 0.6757 0.92 (0.66 – 1.28) 
Controls 476 0.00 0.15 0.85     
GENE Haplotype 
Haplotype Frequency 
χ2 P value P valuepermutation
b OR (95% CI) 
Cases Controls 
MC4R 
Blocka: rs8087522 – rs11872992 
N1 C-T 0.587 0.541 4.30 0.0381 0.0850 1 
N2 C-C 0.360 0.381 0.93 0.3340 0.0526 1.03 (0.74 – 1.44) 
N3 T-C 0.053 0.078 5.17 0.0210 0.056 0.65 (0.45 – 0.94) 
  
 
 
 
 
 
 
 
CHAPTER 5: Discussion  
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This study has validated the association between TB and both CTSZ and MC3R which 
was first identified in a genome-wide linkage study. A number of linkage analyses have 
been conducted in an attempt to identify novel loci involved in susceptibility to TB. In 2000, 
Bellamy et al. [228] found evidence that chromosomes 15q and Xq may have linkage to 
TB while Greenwood et al. [229] found significant linkage with chromosome region 2q35. A 
study of the Brazilian population implicated chromosomes 10, 11 and 20, [230] and in a 
study of a Moroccan population, Baghdadi et al. [230] showed significant linkage between 
TB and chromosome 8q12-q13.  
A genome-wide linkage study performed in 2008 by Cooke et al. [82] identified a locus on 
chromosome 20q13.31-33 containing CTSZ and MC3R, which showed linkage with TB 
susceptibility. Later in 2008, Stein et al. [231] performed a genome linkage study in a large 
population from Uganda and replicated this finding (p = 0.002), identifying a 25 cM long 
region containing both CTSZ and MC3R.  
An independent, unrelated case-control study has now been performed in an SAC 
population and the results of this study show that the same SNP implicated in CTSZ by 
Cooke et al. [82], rs34069356, was associated with TB disease. The OR of 0.28 found in 
this study falls at the lower limits of the CI found by Cooke et al. [82], with a smaller CI. 
This indicates the possibility of an even larger effect size than initially thought. This 
polymorphism results in a non-conservative amino acid change of a non-polar alanine to a 
polar, uncharged threonine.  
CTSZ acts as a carboxypeptidase, similar to cathepsin B, but with specificity to a different 
profile of substrates and inhibitors. While mRNA expression of this gene is found in a large 
number of locations including lung, liver, kidney, pancreas and small intestines [232], it has 
been found that protein levels are highest in lung bronchoepithelial cells, alveolar and 
tingible body macrophages [178]. In all cell types investigated, CTSZ showed a higher 
distribution in lysosomal areas than in the cytoplasm [180]. Localization of this protein 
differs between immature and mature cells and Obermajer et al. [180] showed that in the 
presence of a CTSZ inhibitor, the migration of mature dendritic cells was significantly 
reduced. CTSZ also showed co-localization with β2 integrins in differentiated U-937 cells, 
some Mo-T-lymphocytes and PBMCs, with the strongest signal occurring in cell-cell 
junctions [233]. Expression of the β2 integrin family is characteristic of cells belonging to 
the immune system and it is known to play a central role in immunity due to the ability of β2 
integrins to mediate leukocyte adhesion and migration [234]. These findings seem to 
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suggest a role for CTSZ in the processes of inflammation and immune response as well as 
cell signaling and adhesion. Though it does not appear that the amino acid substitution 
investigated here occurs in an active site on CTSZ, the introduction of a hydroxyl side 
chain has many possible implications. Threonine has an uncharged, polar side chain, 
making the amino acid hydrophilic. Unlike alanine (a hydrophobic amino acid typically 
located on the interior of a protein), threonine is typically located on the exterior of a 
protein where the hydroxyl side chain is free to interact with surrounding water molecules. 
Threonine, but not alanine, is also subject to a number of PTMs including phosphorylation 
by threonine kinases, O-linked glycosylation and acetylation [24, 192, 235]. 
Phosphorylation is known to regulate the activity of proteins and since the amino acid 
substitution introduced by SNP rs34069356 occurs close to the N-terminal of the protein it 
is likely that this threonine is available for phosphorylation. The introduction of a hydroxyl 
group and a number of PTMs is likely to affect protein folding, intracellular localization and 
protein activity. While this case-control study is limited by the sample size, it does provide 
convincing evidence of a role for CTSZ in TB pathogenesis. Future studies should 
investigate the effect of the associated variant on PTMs of this protein and their effect on 
protein function. Understanding the effects of this variant could lead to a better 
understanding of this protein’s role in the pathogenesis of TB. 
A variant located 373bp upstream of the MC3R gene which resulted in a change from a G 
allele to a T allele (rs6127698) was significantly associated with TB, even after stringent 
Bonferroni correction for multiple testing. This SNP is predicted by Genomatix to create an 
alternative transcription factor binding site (http://www.genomatix.de/). The effects of the 
creation of an alternative transcription factor binding site are difficult to predict as a 
polymorphism in this region may result in either an increase or decrease in the 
transcription of the MC3R gene. The SNP in the single exon of MC3R identified by Cooke 
et al. [82] (rs3827103) was not significantly associated in the SAC population used in this 
study. SNP rs6127698 was not genotyped by Cooke et al. [82] and it can be noted that the 
r2 value between rs3827103 and rs6127698 (Figure 4.2) is quite low, indicating that these 
two alleles are not predictive of each other in this SAC population. This might explain why 
Cooke et al. [82] did not find rs3827103 to be associated in their study.  
Functional analysis of the associated SNP in MC3R revealed an increase in gene 
expression in individuals homozygous for either allele when MDMs were stimulated with 
BCG. Although no statistically significant difference was found, individuals of the TT 
genotype showed a trend toward increased MC3R transcription than individuals of the GG 
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genotype. The T allele was found to be overrepresented in controls compared to TB cases 
suggesting that this allele may contribute to a resistance phenotype. The larger increase in 
MC3R expression in individuals homozygous for the T allele suggests that upregulation of 
this gene may somehow aid the host immune system in more effectively containing the 
bacteria upon infection. Mice lacking a functional MC3R protein exhibit an increase in fat 
mass, a decrease in lean mass with no change in overall weight, and even a slight 
decrease in food intake [199]. This increase in feed efficiency is thought to result from an 
increase in the level of consumed energy being sent directly to fat storage. It could be 
reasoned that individuals with less energy available to the immune system might be more 
susceptible to infections. The increase in energy consumption which occurs upon infection 
results from the immune system initiating defense functions including increasing the 
activation and propagation of immune cells, DNA replication, RNA expression and protein 
synthesis and secretion and antigen processing and presentation [235]. It is therefore not 
surprising that undernourishment greatly increases human susceptibility to infectious 
disease, especially in low-income countries [27]. Based on the results of the functional 
analysis performed in this study, MC3R expression is increased upon stimulation with 
BCG. It is plausible that an increased level of MC3R transcript decreases the amount of 
energy being shunted to fat storage making more energy available for the host immune 
response. The limited sample size used in this study, however, makes it difficult to draw 
any definitive conclusions and this study should be repeated using a larger sample size. 
The sensitivity of the qPCR reaction can result in major variation from one run to the next. 
Slight differences in sample purity, sample concentration and assay efficiency can have a 
dramatic impact on cycle threshold. In addition to increasing the sample size, the standard 
deviation could be reduced by running each RNA sample in a serial dilution and by 
normalizing the results of the target gene against more than one reference gene. Due to 
the limited volume of RNA available, running the samples in a serial dilution was not an 
option for this pilot study. It would also be interesting to investigate the change in MC3R 
expression of heterozygous individuals to see if they exhibit an intermediate level of 
increased MC3R expression. Future studies should also investigate the functional role 
MC3R has in the pathogenesis of TB. 
The case-control study investigating the association between TB and three SNPs in MC4R 
did not find any significant difference between cases and controls. Despite this, MC4R 
should not be ruled out as possibly playing a role in TB disease. MC3R and MC4R have 
been found to work together closely performing non-redundant functions. Chen et al. [199] 
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showed that the level of obesity observed in MC4R knockout mice is exacerbated when 
mice also lack MC3R. The synergistic effect of this double knockout may be a result of the 
increase in food intake caused by the lack of MC4R with even more of this increased 
energy consumption being sent directly to fat storage as a result of the increase in feed 
efficiency caused by the lack of a functional MC3R protein. The action of MCRs is coupled 
to adenylyl cyclase activation, and cAMP is able to down-regulate leptin mRNA expression 
in cultured rat adipocytes [27]. Previous studies dealing with the association between 
leptin and TB pathogenesis have been contradictory. In 2002, it was found that TB patients 
in Indonesia showed significantly suppressed plasma leptin concentrations [27] while in 
2003, Schwenk et al. [23] could find no correlation with leptin concentrations and 
proinflammatory cytokine response in active TB, suggesting that this protein was not the 
missing link between immune defense and wasting associated with pulmonary TB [27]. 
These contradictory studies may be due to the fact that the production of leptin is 
regulated by two antagonistic mechanisms [27]. Wasting that is associated with active TB 
may result in a decrease in leptin production while activation of the inflammatory response 
may increase leptin levels [236]. Differences in diet and nutritional status between the 
populations used in each study may also contribute to conflicting results with respect to 
leptin`s involvement in both TB and TB-associated wasting.  
The substantially validated role of MC4R in both obesity and diabetes further supports a 
possible role in TB. Higher BMI values have been shown to increase resistance to TB 
while decreased BMI values showed an increased susceptibility to both the development 
and the severity of TB. A study of HIV-infected individuals in Soweto found a decreasing 
risk of both TB morbidity and mortality with an increasing BMI, showing a dose-response 
effect [206]. These findings are also supported by a study of diabetic individuals conducted 
in 2007. Leung et al. [207] reported that diabetic individuals falling into either the 
overweight or obese BMI range had some protection against TB infection showing a strong 
linear dose-response relationship where for every unit change above a BMI of 18.5, there 
was a 10% reduction in the risk of developing active TB. A higher BMI value typically 
means a larger level of fat stores with a corresponding increase in circulating levels of 
leptin. The increased leptin may result in increased activation of the MC3R leading to a 
stronger host immune response to infection. These findings are contradicted by numerous 
studies which have shown that individuals diagnosed with DM exhibit an increased risk of 
TB infection compared to healthy controls. The above opposing findings are due to the 
complicated relationship between obesity and leptin. It remains debatable whether leptin is 
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a cause or effect of obesity but what is clear is that individuals suffering from obesity are 
chronically exposed to high levels of circulating leptin [237]. This chronic exposure results 
in a decrease in leptin receptor expression, reduced signaling and a decreased 
responsiveness to exogenous leptin [237].  
The opposite of the problem of obesity is that of wasting, a common symptom of TB 
disease with numerous studies showing a decrease in BMI, skin fold thickness and arm 
muscle circumference in TB patients when compared to healthy controls [19]. One cause 
for this muscle wasting may be the result of a decrease in energy consumption as a direct 
result of a decrease in patient appetite, a function shown to be regulated by MC4R 
activation and suppression [20]. A study performed in the USA reported weight loss in 45% 
of TB patients, 26% of which exhibited signs of persistent anorexia [238]. Paton et al. [20] 
reported that patients exhibiting TB-associated wasting weighed an average of 12 kg less 
than healthy controls. 
It would be informative to perform a case-control study of both MC3R and MC4R variants 
where TB patient samples are grouped into those exhibiting the wasting phenotype and 
those who do not. Investigating the effect of inactivating mutations in both MC3R and 
MC4R and their impact on TB disease may also provide valuable insights into the role of 
host metabolism on the development of active TB.  
Observational studies concerning the influence of nutrition on the development of active 
TB go back as far as World War I where Denmark experienced an increase in TB 
morbidity and mortality as the country was exporting the majority of its meat, fish, poultry 
and dairy products [17]. TB rates did not decrease until the Danes experienced a surplus 
of these items following the German blockade of Denmark. As TB rates in Denmark 
decreased, those in surrounding countries continued to rise [17]. Chanarin et al. [236] 
found that in an Asiatic Indian population, life-long vegetarians who were deficient in 
cobalamin (vitamin B12 - a vitamin not found in the plant kingdom) exhibited a significantly 
higher level of TB susceptibility compared to omnivores. Studies investigating the influence 
of weight or nutrition on TB disease noted a significantly lower BMI in those infected with 
TB when compared to healthy controls [199].  
It has been proposed that wasting is one of the determinants of disease severity and 
outcome and this symptom is a prominent feature of TB, particularly in resource-poor 
countries [27]. The mechanism by which poor nutrition leads to lowered cellular immunity 
remains unclear [239]. A number of studies have investigated the effects of nutritional 
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supplements on treatment of the disease but it is equally, if not more, important to study 
the effects of proper nutrition in the prevention of disease. A better understanding of the 
relationship between nutrition and disease susceptibility may provide valuable insights into 
the mechanisms involved in disease progression and suggest cost-effective interventions 
to counter this. The introduction of incentive programs which provide nutritious foods in 
exchange for treatment adherence or encouraging individuals to participate in TB 
screening programs may provide cost-effective ways to improve both treatment adherence 
and detection rates of TB incidence. 
  
 
 
 
 
 
 
 
CHAPTER 6: Concluding Remarks  
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This study provides additional support for host genetics influencing susceptibility to the 
development of TB. The results obtained here have validated previous findings implicating 
CTSZ and MC3R in TB disease. The variant in CTSZ previously associated with TB 
susceptibility in three West African populations was also found to be associated with TB in 
an SAC population. These findings provide convincing evidence for CSTZ playing a role in 
the host immune response to TB infection and motivate future research into the function of 
this gene in the immune response to TB infection and pathogenesis. Determining the 
functional effect of the amino acid substitution caused by the associated variant could 
provide valuable information both on this gene’s role in immunity and how TB is so 
effective at evading elimination by the host immune response. Genotypic and functional 
analyses of MC3R provided evidence that energy expenditure and host metabolism may 
influence an individual’s susceptibility to TB. These results suggest that upregulation of 
this gene may reduce the risk of developing TB by influencing the amount of energy 
available to the host immune system. Due to the fact that MC3R is found to work closely 
while not redundantly with MC4R it is possible that proper nutrition may also play an 
important role in preventing TB. Results of this study encourage further investigations to 
be made into determining the impact of nutritional status both on the prevention and 
progression of TB. Understanding the impact of proper nutrition prior to infection may 
provide a novel strategy for TB prevention programs and may provide a cost-effect 
incentive to improve treatment adherence. It is possible that a better understanding of the 
impact nutritional status has on TB prevention and prevalence may allow for revisions of 
current public health programs leading to a more successful outcome of intervention. 
Genome-wide linkage studies have not always been overly successful at identifying genes 
impacting on complex diseases, but this study illustrates that genes identified this way, 
and not previously suspected to be involved in TB disease, can prove to be convincing 
candidates. 
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